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ABSTRACT 
With an ever-increasing number of people who are getting diagnosed with diabetes, this 
disease presents one of the modern world’s biggest dangers. With our sedentary lifestyle, 
together with increased food consumption, it is more than likely that this increase is not 
going to slow down any time soon. Most patients around the world are diagnosed with type 
2 diabetes, a disease that shares the hyperglycaemia with diabetes type 1, but which origins 
are completely different. While the type 1 diabetes is an autoimmune disease, where our 
own immune system attacks and destroys the insulin-producing pancreatic β-cells thus 
causing hyperglycaemia, type 2 diabetes is caused because target tissues, such as liver, 
muscle and adipose tissues, develop insulin resistance, meaning that insulin fails in its role 
of stimulating glucose intake. This elevated systemic level of glucose causes the increase 
in the insulin production and its secretion from the pancreatic β-cells, as a way to battle 
hyperglycaemia, but this mechanism cannot be sustained by the β-cells indefinitely. This 
increased burden on the β-cells, combined with other factors, which include environmental 
and genetic components, results in pancreatic failure with the concomitant decrease in 
insulin secretion, exacerbating the problem and worsening the blood glucose levels. If this 
unbalance is left unchecked, it will progressively deteriorate, and it can lead to a multitude 
of health complications for the affected individual. One of the important mediators that are 
active in this development of insulin resistance is c-Jun N-terminal kinase (JNK), which is 
a protein that is stimulated by inflammation and stress, two conditions that are regularly 
present in diet-induced obesity. These two conditions activate the JNK, phosphorylating 
the protein and activating it, thus concomitantly inactivating insulin receptor substrate 
(IRS). By inactivating the IRS, JNK consequently prevents the insulin signalling cascade 
propagating its signal and through this kinase, the inflammation and stress cause the 
inhibition of insulin effect. Moreover, JNK also increases the expression of inflammatory 
cytokines, such as tumour necrosis factor α (TNF-α), which then in turn again activate 
JNK, resulting in the spiralling effect, all culminating in the worsening of the tissue insulin 
signalling and increasing the systemic glucose levels. Activation of JNK occurs through a 
mitogen-activated protein kinase cascade, and one of these kinases, known as apoptosis 
signal-regulating kinase 1 (ASK-1), is under the control of protein phosphatase 5 (Pp5). 
This phosphatase is involved in a multitude of different cellular functions, including cell 
proliferation, electrolyte balance, apoptosis and DNA repair, among others. The exact role 
of Pp5 in the development of insulin resistance is still unclear, as some research suggests 
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that Pp5 inhibits ASK-1, and consequently, inhibits the activation of JNK, resulting in 
improved insulin signalling in the insulin targeted tissues. However, conflicting evidence is 
presented, as some researchers showed that mice with inactivated Pp5 gene had increased 
levels of glucocorticoids. These compounds, through their specialised glucocorticoid 
receptors, promote the expression of anti-inflammatory proteins, like interleukin 10, and 
inhibit the expression of inflammatory ones, such as interleukins 1, 2, 6 and others. 
Lowering of inflammation also causes less inflammatory cytokines, leading to less JNK 
activation, and consequently, better insulin signalling in the targeted tissues.  
Finally, it is important to also consider the role liver X receptors (LXR) have in the insulin 
sensitivity. These receptors regulate the expression of genes that partake in lipid 
biosynthesis and carbohydrate metabolism, among others. With its variety of effects on 
multiple genes involved in lipid metabolism and anti-inflammatory effect, and with studies 
showing that LXR ligands activate the expression of Pp5, these receptors and their ligands 
could present a novel new way for the treatment of diabetes. GW3965 is one of these LXR 
agonists, and this non-steroidal compound could represent a novel new group of 
antidiabetic drugs.  
In our study, we were interested how different physiological mediators, such as JNK, are 
involved in the development of diet-induced obesity and insulin resistance, and how they 
influence the onset of type 2 diabetes. Another aspect we were interested in was how these 
mediators interact with Pp5 and how they change its role, if it all has any, in the progress 
of the insulin resistance. For this purpose, we analysed how inflammation induced by the 
obesity is expressed and how it influences the insulin signalling cascade in three different 
mice tissues: skeletal muscle, liver and epididymal white adipose tissue. We used wild-
type and genetically altered mice with inactivated Pp5 gene. These animals were then 
further divided into 2 groups, where one was kept on a standard diet, and the other on the 
high-fat diet. After 10 weeks, we divided the subjects into 2 groups and treated one with 
the LXR ligand GW3965. Glucose tolerance test and insulin tolerance test were performed, 
half of the animals in the experiment received insulin just before they were sacrificed, and 
their tissues were collected. With the use of immunoblotting, we evaluated the activation 
levels of protein kinase B (AKT), which is a protein activated in the process of insulin 
signalling, and JNK. In addition, we analysed the effect of LXR agonist GW3965 on the 
development of insulin resistance. Finally, using quantitative polymerase chain reaction, 
we analysed the expression of Slc2a4, the gene that encodes glucose transporter type 4 
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(GLUT4), one of the main transporters for glucose intake, and the pro-inflammatory 
cytokine TNF-α in the skeletal and epididymal adipose tissues. 
From the AKT data, we were able to conclude that animals, which were fed with the high-
fat diet, developed resistance to insulin signalling. Analysis of the JNK activation showed 
that in epididymal white adipose tissue GW3965 lowered the phosphorylation of the 
protein, making it less active and lowering the inflammation signalling. With this decrease 
of inflammation, insulin signalling is improved, and these data indicate that GW3965 is a 
potential new antidiabetic medication. However, it is difficult to draw more concrete 
conclusions, as the liver tissue results did not corroborate results from adipose tissue, 
indicating that the influence of LXR agonists could be limited to certain tissues. RNA 
experiments in the muscle and epididymal white adipose tissue displayed lowered GLUT4 
expression levels in the mice which had developed insulin resistance. But interestingly, 
epididymal white adipose tissue taken from mice that were treated with GW3965 showed a 
significant increase in the Slc2a4 gene expression, adding additional evidence that this 
tissue is where this compound could be used with the most benefits. 
The role of Pp5 in diet-induced obesity and insulin resistance remains elusive though, as 
we could not draw any concrete conclusions from the experiments. From the data we 
gathered we can state that Pp5 deletion, with concurrent use of GW3965, inhibits the 
activation of JNK, thus improving insulin signalling pathway, with the consequence being 
a higher expression of the GLUT4 gene. But some contradictory data also seem to be 
present, as liver samples especially displayed unusual behaviour, with Pp5 deletion causing 
an increase of JNK activation in the presence of GW3965.  
 
 
 
 
 
 
 
 
 
 
 
Keywords: diabetes, diet-induced obesity, insulin resistance, protein phosphatase 5 
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POVZETEK 
V današnjem svetu je vse več ljudi, katerim se diagnosticira diabetes, zaradi česar je ta 
bolezen ena izmed največjih nevarnosti, ki nam pretijo v prihodnosti. Zaradi našega 
sedečega načina življenja, uživanja večjih količin hrane in pomanjkanja gibanja je več kot 
verjetno, da se bo število novih pacientov le povišalo. Večina bolnikov po svetu ima 
diagnosticiran diabetes tipa 2, bolezen, ki sicer deli hiperglikemijo z diabetesom tipa 1, a je 
ta popolnoma drugega izvora. Medtem ko je diabetes tip 1 avtoimunska bolezen, kjer naš 
lastni imunski sistem napade in uniči β-celice ledvične žleze, ki proizvajajo inzulin, je tip 2 
posledica odpornosti tarčnih tkiv, kot je jetrno, mišično in maščobno tkivo, na inzulinsko 
signalizacijo, kar pomeni, da inzulin ne opravi svoje naloge, tj. prevzema glukoze. Ta 
povišan sistemski nivo glukoze povzroči povišano sintezo in izločanje inzulina iz β-celic 
trebušne slinavke kot mehanizem proti hiperglikemiji, a tega mehanizma β-celice ne 
morejo vzdrževati v nedogled. Povečan pritisk na trebušno slinavko skupaj z ostalimi 
dejavniki, med katerimi so tudi okoliški in genetski, povzroči opešanje in propad β-celic, in 
zaradi tega tudi zmanjšanje izločanja inzulina, kar še bolj poslabša problem. Če to 
neravnovesje pustimo brez nadzora, se bo sčasoma le poslabšalo, kar na koncu lahko 
pripelje do mnogih zdravstvenih težav za osebe, ki trpijo za to boleznijo. Eden izmed 
pomembnih posredovalcev, ki so aktivni v razvoju inzulinske odpornosti, je c-Jun N 
terminalna kinaza (JNK), protein, ki ga aktivirata vnetje in stres, dve stanji, ki sta značilni 
za s prehrano povzročeno debelost. Ko se JNK aktivira, ta forforilizacija povzroči 
inaktivacijo substrata inulinskega receptorja (IRS). S to inaktivacijo JNK posledično 
prepreči, da se signal inzulina širi naprej, in preko te kinaze vnetje in stres spodbudita 
razvoj inzulinske odpornosti. Hkrati JNK poviša izražanje vnetnih citokinov, kot je 
dejavnik tumorske nekroze α, ki dodatno aktivirajo JNK in tako se ustvari začaran krog, ki 
pripelje do slabšanja odzivnosti tkiv na insulin in hiperglikemije. Aktivacija JNK poteka 
skozi kaskado mitogensko aktiviranih protein kinaz, med katerimi je tudi signal apoptoze 
regulirajoče kinaze 1 (ASK-1), le-ta pa je pod vplivom protein fosfataze 5 (Pp5). Ta 
fosfataza je vključena v mnoge celične funkcije, med katerimi so celična delitev, 
ravnotežje elektrolitov, apoptoza, popravilo poškodb DNA in druge. Natančna vloga tega 
proteina v razvoju inzulinske odpornosti ni še popolnoma jasna, saj nekatere raziskave 
kažejo, da Pp inhibira ASK-1 in posledično inhibira aktivacijo JNK, kar vodi v izboljšanje 
inzulinske signalizacije v tarčnih tkivih. Vendar, nasprotna dejstva so prisotna, saj so 
nekateri raziskovalci pokazali, da so miši, ki so imele onesposobljen gen za Pp5, imele 
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povišane nivoje glukokortikoidov. Te spojine delujejo preko posebnih glukokortikoidnih 
receptorjev, spodbujajo izražanje protivnetnih mediatorjev, kot je interlevkin 10, in hkrati 
zavirajo izražanje vnetnih mediatorjev, kot so interlevkin 1, 2, 6 in ostali. Zmanjšanje 
vnetnih dejavnikov povzroči manjšo aktivacijo JNK, kar se izrazi kot izboljšano inzulinsko 
signaliziranje. 
Na koncu je vredno tudi omeniti vlogo jetrnih receptorjev X (angleško liver X receptor ali 
LXR) na inzulinsko občutljivost. Ti receptorji nadzorujejo izražanje genov, ki so vpleteni, 
med drugim, v biosintezo lipidov in metabolizem ogljikovih hidratov. Z mnogimi 
različnimi efekti na gene, vključene v lipidni metabolizem, in proti vnetnim učinkom, 
dodatno podprto s podatki, ki kažejo, da LXR ligandi aktivirajo izražanje Pp5, prestavljajo 
ti receptorji in njihovi ligandi nov način zdravljenja diabetesa. GW3965 je eden izmed teh 
ligandov, ki aktivirajo LXR in bi mogoče lahko omogočil razvoj nove skupine 
antidiabetičnih zdravil. 
V tej raziskavi nas je zanimalo, kako so različni fiziološki mediatorji, kot je JNK, vpleteni 
v razvoj s prehrano povzročene debelosti in inzulinske odpornosti in kako vplivajo na 
razvoj diabetesa tipa 2. Dodatno nas je zanimalo tudi, kako ti mediatorji vplivajo na Pp5 in 
kako spremenijo vlogo te fosfataze, če jo sploh ima, v razvoju inzulinske odpornosti. Zato 
smo analizirali, kako se zaradi debelosti povzročeno vnetje izrazi in kakšen je vpliv le-tega 
na inzulinsko signaliziranje v treh različnih mišjih tkivih: skeletnem mišičnem, jetrnem in 
belem maščobnem tkivu. Uporabili smo miši divjega tipa in gensko spremenjene miši z 
inaktiviranim genom Pp5. Živali smo naprej razdelili v dve skupini, kjer smo eno skupino 
hranili s standardno dieto, drugo pa z dieto z veliko količino maščob. Po desetih tednih 
smo miši naprej razdelili v dve skupini, kjer je ena skupina prejemala ligand LXR 
(GW3965). Izvedli smo glukozni tolerančni test in inzulinski tolerančni test, polovica 
živali pa je tik pred žrtvovanjem prejela inzulin, nakar smo odvzeli izbrana tkiva. Z metodo 
prenosa western smo preverili stopnjo aktivacije proteinske kinaze B (AKT), ki je protein, 
aktiviran v procesu inzulinskega signaliziranja, in stopnjo aktivacije JNK. Dodatno smo 
preverili tudi, kakšen vpliv ima agonist LXR GW3965 na razvoj inzulinske odpornosti. Na 
koncu smo z uporabo verižne reakcije s polimerazo v mišičnem in v maščobnem tkivu 
analizirali izražanje gena Slc2a4, ki kodira glukozni transporter (GLUT4), enega izmed 
glavnih mediatorjev za prevzem glukoze v prej omenjenih tkivih, in gena za vnetni citokin 
TNF-α.. 
Iz podatkov, ki smo jih dobili iz analiz AKT, lahko sklenemo, da so živali, ki smo jih 
hranili s hrano bogato z maščobami, razvile rezistenco na inzulinsko signaliziranje. 
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Analiza podatkov o JNK v maščobnem tkivu je pokazala, da je GW3965 znižal 
fosforilizacijo te kinaze (tj. znižal je stopnjo njene aktivacije), kar je pomenilo zmanjšanje 
vnetnega odziva. S tem znižanjem se inzulinsko signaliziranje izboljša in ti podatki 
nakazujejo, da bi v prihodnosti ta mehanizem lahko izkoriščala nova antidiabetična 
zdravila. Vendar bolj konkretni zaključki le niso možni, saj nam rezultati analiz iz jetrnega 
tkiva niso potrdili prej razložene rezultate, kar možno nakazuje, da je vpliv agonistov LXR 
omejen na le nekatera tkiva. Kvantifikacija izražanja genov na nivoju RNA v mišičnem in 
belem maščobnem tkivu je pokazala, da je izražanje prenašalca GLUT4 veliko nižje pri 
miših, ki so razvile inzulinsko odpornost kot posledico prehrane, a smo v maščobnem tkivu 
zaznali povišano izražanje gena za ta transporter, in sicer pri živalih, ki so prejele 
GW3965. To je dodaten dokaz, da je prav to tkivo tisto, kjer bi spojine, kot je GW3965, 
lahko imele najbolj koristen vpliv na zdravljenje sladkorne bolezni tipa 2. 
Vloge Pp5 v s prehrano povzročeni debelosti in razvoju inzulinske odpornosti nismo uspeli 
razjasniti bolj podrobno, saj nam niti analiza aktivacije encimov niti analiza izražanja 
genov na nivoju RNA nista podali statistično značilnih rezultatov. Iz dobljenih podatkov 
lahko rečemo, da inaktivacija gena Pp5 skupaj z uporabo GW3965 zmanjša fosforilizacijo 
in s tem aktivacijo JNK ter da tako izboljša inzulinsko signaliziranje, saj se zviša izražanje 
gena za prenašalec GLUT4. A še vedno obstajajo nasprotujoči si podatki, saj je še posebej 
jetrno tkivo pokazalo nasprotno vedenje, kjer je bila aktivacija JNK pri enakih pogojih 
višja kot pa v primeru, ko nismo aplicirali GW3965 in ko je bil gen Pp5 funkcionalen. 
 
 
 
 
 
 
 
 
 
 
 
 
Ključne besede: diabetes, s hrano povzročena debelost, inzulinska odpornost, protein 
fosfataza 5  
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1. Introduction 
1.1. Obesity and Diabetes 
Obesity is one of the modern world most pressing issues. World Health Organisation 
(WHO) defines obesity as abnormal or excessive fat accumulation that presents a risk to 
health (1), and it occurs when during the longer period our energy intake is greater than the 
energy expense (2). Depending on where the fat tissue accumulates, we differentiate 
between 2 types of obesity: visceral type, where fat accumulates mostly in the abdominal 
cavity, and peripheral type, where fat accumulates subcutaneously (2). There are myriad of 
ways of how to classify obesity and stages of it, most prevalent of these being the 
calculation of Body Mass Index (BMI), which is obtained by dividing the weight in 
kilograms with the square of the height in metres (kg/m2). Less used methods include waist 
circumference and central and peripheral fat mass measurements, but currently BMI is 
internationally accepted method and used by researchers dealing with this topic (3).  The 
categories of BMI according to WHO are presented in Table I (4). 
Table I: BMI categories defined by WHO 
BMI Category 
Bellow 18,5 Underweight 
18,5-24,9 Normal weight 
25,0-29,9 Pre-obesity 
30,0-34,9 Obesity class I 
35,0-39,9 Obesity class II 
Above 40 Obesity class III 
  
In the last decades, there is a clear sign that modern society, especially in most developed 
countries, is getting progressively more obese. WHO in their 2018 World health statistic 
report (5) stated that there was more than a 10-fold increase in the number of obese 
children and adolescents aged 5-19 years, just in the past four decades. Statistics show that 
obesity in adults is no different, with numbers stating 39 % of women and 39 % of men 
aged 18 and older were overweight in 2016 (BMI 25,0 or more), while 15 % of women and 
11 % of men were obese (BMI over 30,0) (6). If we put these statistics into more 
presentative numbers, we see that approximately 2 billion adults are overweight, which 
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indicates that this is an enormous problem the modern world is facing, and numbers are 
expected to continue to rise. 
This rapidly increasing rate of weight gain in individuals is caused by a range of different 
aspects, such as environmental influences, social factors that influence individual 
behaviour, early life experiences and inherited biological traits (7). Humans throughout 
history and evolution developed systems that are optimised for energy storage, as in the 
past high energy food was sparse and there were periods with food shortages. But in the 
current world, high energy food is widely available and periods of food shortages, at least 
in the developed world, are virtually non-existent. This results in high energy intake, which 
is not offset by energy expenditure, as in modern-day lifestyle, which is mostly sedentary, 
individuals are not active and do not use up the energy they received from food. Moreover, 
limbic and dopamine systems give an individual a feeling of reward by food intake (2), and 
this motivates further food intake, especially highly rewarding foods such as sugar and fat-
rich type (7). Additionally, researchers studied the genetic effect on obesity, and numerous 
hypotheses were developed, but until now, there was no theory developed that could 
explain all the genetic influences on obesity.  
All the stated factors, and many more, together combine into a complex network of 
influences and reason why our society is getting obese and solving it is one of the biggest 
difficulties we are facing today, as obesity plays a factor in numerous diseases and 
increases the probability of appearance of some types of illnesses. Obesity is one of the 
risk factors that define metabolic syndrome, increases the number of patients with 
hypertension, atherosclerosis, cardiovascular problems, liver diseases, and many others. 
One of the diseases where obesity has a major influence and is the central illness of our 
research is insulin resistance and the development of type 2 diabetes mellitus. 
Diabetes mellitus, more commonly known as diabetes, is a complex group of metabolic 
disorders, with a common sign being hyperglycaemia (2), which is the end result of lack of 
insulin or its effects. Insulin is a 51-amino-acid-residue peptide, which is synthesized as a 
precursor pre-proinsulin in β-cells of the pancreas. This precursor includes an N-terminal 
signalling peptide, which is cleaved by signal peptidase and converts it into proinsulin, 
which is then translocated into the endoplasmic reticulum (ER) where it is packaged into 
vesicles and where proinsulin is split into mature peptide insulin and peptide C. Secretion 
of insulin (Fig. 1) starts with the rise of the glucose level in the bloodstream, as glucose 
travels with the blood to the pancreas, and it enters into the β-cells through glucose 
3 
 
transporters (GLUT), mainly of type 2. Once in these cells, glucose is metabolized by the 
glycolytic pathway producing the increase of ATP/ADP ratio in the cells. This increase 
results in inhibition of ATP-dependent K+ channels, which leads to the depolarization of 
the membrane through the entry on Na+ ions, and this causes the opening of voltage-
dependent Ca2+ channels. This increase of intracellular Ca2+ level is the signal that causes 
the translocation of insulin-containing vesicles to the membrane and exocytosis of insulin 
into the bloodstream (2). Inhibition of K+ ion channels is a mechanism that some anti-
diabetic medications make use of. Some other factors, such as amino acids or free fatty 
acids, also increase the influx of Ca2+ ions into the cells and cause the exocytosis of 
insulin. Once insulin is released, it enters the portal vein and is taken to the liver, where 
insulin plays its most important role in lowering gluconeogenesis, glycogenolysis, 
lipolysis, ketogenesis and protein degradation, and increases glycogenesis, synthesis of 
free fatty acids and glycerol (2). The liver is also a place where around 50% of insulin gets 
metabolised, and the remaining half that comes out of the liver produces its effects on other 
target tissues, such as adipose and muscle tissues among others. In these tissues, insulin 
binds to its receptors and sets a signalling cascade into motion. 
 
Figure 1: Insulin secretion from the pancreatic β-cells (see text for explanation). Adapted from (2). 
If any of these complex mechanisms do not function properly, and the insulin effect is not 
achieved properly, hyperglycaemia, the characteristic of diabetes, develops. Main types of 
diabetes are type 1, type 2 and gestational diabetes, with the latter appearing in women 
during pregnancy, and will not be discussed hereafter. 
Type 1 diabetes is characterized as an autoimmune disease, where the immune system of 
an individual attacks and destroys the β-cells of the pancreas and is usually diagnosed in 
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the younger population. Why exactly this kind of immune response occurs is not yet 
completely elucidated, but many complex factors contribute to its development, including 
genetic predisposition, environmental influences and immunological factors. Researchers 
have identified different specific genes that are present in patients with type 1 diabetes, 
indicating an important role of genetics in the development of this disease. One of the most 
important genetic factors is a gene complex called human leukocyte antigen (HLA), which 
is the human version of the major histocompatibility complex (MHC) found in other 
vertebrate species. This gene complex encodes glycoproteins present on the surface of the 
cells which are important for the regulation of the immune system, as these proteins play a 
key role in the activation of the adaptive immune system, considering these proteins are 
responsible for the recognition of antigens presented to the immune system (2). The exact 
reason why some alleles of HLA genes play such an important role in the development of 
type 1 diabetes is not yet completely understood, but researchers did manage to discover 
some of the autoantigens that take part in the pathogenesis of type 1 diabetes, with some of 
them being insulin, glutamic acid decarboxylase and cation efflux transporter ZnT8, 
among others (8).  More recently, it was discovered that defective ribosomal products, 
which can occur during insulin synthesis, are more likely to be presented to the immune 
system by certain HLA alleles, which have been previously categorised as alleles with the 
highest potential for type 1 diabetes (9). This increase in ribosomal errors is recognised by 
our immune system as the product of dysfunctional cells, and the immune system is trained 
to recognise these cells and destroy them. Thus, the attack on β-cells causes the 
development of type 1 diabetes. But this genetic predisposition to type 1 diabetes 
development is exactly that, a predisposition, its presence is not enough, and other 
contributors are needed in the development of the disease, with an increasing amount of 
evidence of the important presence of environmental factors. Oftentimes, but not in every 
case, researchers found that some viral infections played a key role in the onset of the 
disease (10), although the precise mechanism of how this occurs is still unknown. A couple 
of ways on how viral infections can trigger the illness have been proposed, by either 
directly destroying the β-cells in the pancreas, or, as the infection causes the inflammation 
of the pancreas, this sets off an immune system reaction where it recognises the previously 
mentioned autoantigens (2). Moreover, some have suggested the influence of diet and gut 
microbes. Although the real cause of type 1 diabetes eludes discovery, what is certain is 
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that it is a complex set of diverse factors, where most, if not all, are intertwined into a web, 
overlapping, and causing this illness.  
While the number of patients suffering with type 1 diabetes is ever-growing, and the need 
for new and more effective medications is increasing, this type only represents a relatively 
small number of diabetic sufferers, as much more prevalent type is type 2 diabetes, with 
International Diabetes Foundation stating 90% of all diabetic patients are afflicted with this 
type (11).  
Type 2 diabetes is usually diagnosed in adulthood and typically correlates with 
overweight/obesity and, in a high number of cases, with other disorders from the metabolic 
syndrome constellation. Although this type shares the sign of hyperglycaemia with type 1 
diabetes, it is fundamentally a different illness, where insulin resistance of insulin target 
tissues and the impaired insulin secretion from pancreatic β-cells, are the 2 crucial factors 
in the development of the disease. These two causes are interlinked and inseparable in the 
aetiology of the illness, albeit evidence suggesting that the tissue resistance is the primary 
cause, with the impaired insulin secretion occurring as the result of pancreatic failure due 
to increased insulin motivated by systemic insulin resistance. Why this signalling 
resistance occurs is a complex and not yet completely understood, but nonetheless, genetic 
influences, as well as environmental impact, are proven to play an important role.  
Researchers connected gene polymorphisms for genes like peroxisome proliferator-
activated receptor gamma (PPAR-γ), insulin receptor substrate (IRS) and calpain 10, 
among others (2), with having an influence on this occurrence. Although these genetic 
factors need to be present for the development of type 2 diabetes, environmental factors are 
just as important, with obesity having the most prominent influence (2). In obesity, over-
expanded adipose tissue is known to increase the circulating levels of free fatty acids, 
which in turn lowers the consumption of glucose by peripheral tissues like muscle tissue, 
increases the glucose release from the liver and, finally, also damages the pancreatic β-
cells (2). But free fatty acids are not the only ones influencing insulin signalling sensitivity, 
with adipose tissue releasing other compounds, such as pro-inflammatory signalling 
molecules, which additionally lower the insulin sensitivity. This effect of obesity, 
combined with other environmental factors like physical inactivity and genetic influences, 
is causing the rising number of patients suffering with type 2 diabetes. Moreover, in the 
development of the disease another component cannot be ignored, and that is the 
impairment of insulin secretion from pancreatic β-cells. With impaired insulin sensitivity 
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of tissues, a need for higher levels of insulin secretion is required to maintain 
normoglycemia. This increased demand cannot be sustained, and after some time, β-cells 
start to progressively fail and die, with some signs stating genetics has influence in this cell 
destruction, even though the definite cause is still unknown. 
All these pieces together form a puzzle that is obesity and obesity-associated type 2 
diabetes, diseases that are among the modern world biggest concerns, and with obesity-
induced insulin resistance the major link between obesity and its associated disorders. 
 
1.2. Insulin Signalling  
When insulin arrives at the targeted tissue, it binds to the insulin receptors (IR) at the 
cellular surface. These receptors are present in basically all human cells and, depending on 
the targeted tissue, different signalling cascades are put into motion. Briefly, in liver 
insulin stimulates glycogenesis and triglyceride synthesis while lowers gluconeogenesis 
and lipolysis; in muscle, it stimulates the uptake of glucose and protein synthesis; and in 
adipose tissue glucose and free fatty acid uptake is promoted (12). 
The insulin receptor belongs to the tyrosine kinase receptor family group. It is a tetrameric 
protein, comprised of 2 α-subunits, on which the ligands like insulin and insulin-like 
growth factor 1 (IGF-1) bind, and 2 β-subunits, which are transmembrane subunits with 
intrinsic tyrosine kinase activity in the cytoplasmic tail. After ligand engagement, 
structural changes in the receptor are induced, with the autophosphorylation of the tyrosine 
residues in the β-subunits being the end result. These phosphotyrosine residues become 
platforms for docking of the IRS family of proteins, like IRS-1, which also undergo IR-
mediated tyrosine phosphorylation. For example, phosphorylation of tyrosine 612 of IRS-1 
serves the purpose of being the docking site for the binding of the signalling proteins that 
are involved in the next steps of the insulin signalling pathway, among these being 
phosphatidylinositol-3-kinase (PI3K), p85 and Grb2-SOS adaptor Shc (13). PI3K 
recruitment near the membrane, mediated by its interaction with IRS-1, produces the 
synthesis of phosphatidylinositol-3,4,5-trisphosphate (PIP3), and the subsequent 
recruitment of phosphoinositide-dependent kinase (PDK). PKD phosphorylates serine 473 
of protein kinase B (AKT), a serine/threonine kinase that is the key member of the insulin 
signalling pathway (Fig. 2) (13). Through AKT, insulin triggers many of its effects and 
sets in motion numerous cellular mechanisms of glucose metabolism, while also promoting 
the metabolism of lipids though sterol-regulatory element-binding protein (SREBP)-1c. 
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Figure 2: AKT activation through PI3K (see text for explanation). Adapted from (12). (IRS-1 – insulin 
receptor substrate 1; PI3K - phosphoinositide 3-kinase; PIP – phosphatidylinositol phosphate; PDK - 
pyruvate dehydrogenase kinase; AKT – protein kinase B). 
IRS-1 phosphorylation does not only cause the propagation of the insulin signalling, as the 
same mechanism of attaching the phosphoryl group but to a different IRS amino acid 
inhibits the signalling cascade. For example, phosphorylation of IRS-1 on serine 307 
inhibits insulin signalling. This mechanism, which is induced by insulin, constitutes a 
negative feedback loop, and it is carried out by c-Jun N-terminal kinase (JNK) (13). 
  
1.3. c-Jun N-terminal Kinase 
c-Jun N-terminal kinases, also known as JNK, are an assembly of serine/threonine kinases 
that belong to the stress-activated protein kinases (SAPK) subfamily of mitogen-activated 
protein kinase (MAPK) family. JNK is stimulated by inflammatory signals like tumour 
necrosis factor (TNF)-α, and stress stimuli like ultraviolet light, and participate in a broad 
cluster of signalling pathways and cellular regulatory processes, including gene 
transcription, protein synthesis and apoptosis, among others (13). JNK plays an important 
role in obesity-induced insulin resistance, therefore it is of utmost importance to 
familiarize with this intricate pathway.  
JNK is encoded by 3 genes, jnk-1, jnk-2 and jnk-3, and with different splicing mechanisms 
12 isoforms are present in humans (13). Like other MAPKs, JNK is the final step in a 
protein kinase cascade module, a system of enzymes that include MAPK, a MAPK kinase 
(MAP2K) and MAP2K kinase (MAP3K), with scaffolding protein present in many of 
these modules to help stabilize the interactions between the kinases. When a signal is 
propagated to the module, the first kinase that is activated by double phosphorylation is the 
MAP3K, which then phosphorylates and activates, in the same manner, the MAP2K and 
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that in turn phosphorylates and activates the MAPK (13). When the signal has been 
transferred further down the pathway, the kinases are inactivated by dephosphorylation by 
protein phosphatases. 
JNK is a part of a triple protein kinase module, with JNK interacting protein (JIP-1) or 
arrestin being also present as scaffolding part required for the module stabilization. While 
multiple different MAP3K have been discovered, only two JNK MAP2K have been 
identified - MKK4 and MKK7, where the latter is highly specific for JNK. When the 
phosphorylation of JNK occurs, it dissociates from the module and subsequently its 
translocation into the nucleus of the cell, where it, in turn, phosphorylates and activates c-
Jun protein (Fig. 3). c-Jun is one of the components of the AP-1 complex, which is an 
assemblage of the protein linked to DNA binding elements called TPA (12-O-
tetradecanoylphorbol-13-acetate)-responsive element (TRE) and is present, among others, 
in many pro-inflammatory genes. When this complex is inactive it is bound to co-
repressors that block the transcription of AP-1 target genes. However, upon JNK-mediated 
c-Jun phosphorylation co-repressors dissociate, which in turn enables the interaction with 
co-activators, triggering target gene transcription (13). JNK signalling is inactivated by 
dephosphorylation by nuclear protein phosphatases, which is followed by JNK 
translocation back into the cytoplasm. 
As stated before, JNK pathway is stimulated by different stress stimuli, such as ER stress, 
reactive oxygen species (ROS) accumulation and inflammation, conditions that are present 
in the over-expanded adipose tissue of obese patients. Therefore, there is an important 
association between exacerbated JNK signalling and insulin resistance, which we will 
explore in more detail below. 
 
Figure 3: JNK regulation of gene transcription. Adapted from (13). (JIP-1 – JNK interacting protein 1; 
MLK – mixed-lineage kinase; MKK7 – mitogen-activated kinase 7; TRE - tetracycline response element; 
JNK – c-Jun N terminal kinase). 
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1.4. Obesity-Induced Insulin Resistance 
Inflammation is the linking piece that connects obesity and insulin resistance, as 
researchers observed increased levels of TNF-α gene expression in adipose tissue of obese 
rodents and humans, causing increased levels of this cytokine locally, and as time 
progressed, systematically. Further experiments, where TNF-α gene was knocked out and 
insulin sensitivity was improved, gave yet more traction to the connection between 
inflammation and insulin resistance (13). 
In the case of obesity, both hyperplasia and hypertrophy of adipocytes occur, with the 
result being the alteration of the cell functioning. Greater demand for protein synthesis, 
accumulation of unfolded protein in the endoplasmic reticulum, which induces ER stress, 
and superfluous production of ROS that damage the endoplasmic reticulum are just some 
of these changes that the cells try to fight with the unfolded protein response (UPR). This 
is an elaborate system required to restore organelle functionality, and one of the systems 
that participate in this response is the activation of JNK pathway mediated with the 
inositol-requiring enzyme (IRE)-1 through TNF-receptor associated factor (TRAF)-2 (13). 
Activated JNK carries out different functions, like the phosphorylation of IRS on serine-
307, resulting in the inhibition of insulin signalling pathway, and the induction of 
inflammatory gene expression, causing a further increase of JNK activity. Moreover, in 
obesity, the systemic levels of free fatty acids are increased and through their binding to 
the toll-like receptors also activate the JNK pathway and further contributing to the 
development of insulin resistance (Fig. 4) (13).  
 
 
Figure 4: Different JNK activation pathways, which result in its overactivation. Adapted from (13). 
(ROS – reactive oxygen species; IRE-1 - inositol-requiring enzyme; TRAF - TNF receptor-associated factor). 
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Further genetic evidence validated the central role of JNK in obesity-induced insulin 
resistance even more.  Studies about JIP-1, a scaffold protein of the JNK module, 
established it as one of the factors in type 2 diabetes development (14), with further 
experiments exhibiting protection against obesity-induced insulin resistance in JIP-1 
knockout mice (15).   
Moreover, researchers discovered that Jnk-1-deficient mice do not develop obesity in 
response to diet and showed improved insulin sensitivity and IR signalling. The same study 
also showed that some isoforms of the JNK, like JNK-1, have a more prominent role in the 
development of obesity-induced insulin resistance (16). Additional evidence of the 
importance of the role JNK in type 2 diabetes was obtained when the mechanism of the 
insulin-sensitizing drugs called thiazolidinediones was discovered. This family of drugs are 
ligands of PPAR-γ and carry out their insulin-sensitizing action by inhibiting obesity-
induced JNK activity (17). 
When all these changes in cellular systems occur, they affect particular tissues differently, 
resulting in a variety of changes in the physiology of the individual elements. Adipose 
tissue-specific Jnk-1 gene knockout did not prevent the development of obesity in mice, 
although the subjects were protected from the development of diet-induced insulin 
resistance (18).  There was evident protection against insulin resistance in obese mice with 
JNK activity inhibition in the liver tissue, although there is some discussion regarding the 
role of liver JNK isoforms in the systemic glucose metabolism. Some results show that jnk-
1 gene inactivation in the liver results in reduced hyperglycaemia and hyperinsulinemia, 
but with noticeable effects on hepatic steatosis (19). Additionally, when researchers 
inactivated specific Jnk-1 gene in hepatocytes, it resulted in induction of glucose 
intolerance, insulin resistance and hepatic steatosis in the lean mice, and had no effect in 
obese mice, demonstrating a protective function of specific JNK isoforms in the liver (20). 
These disparities are likely due to the dual function of JNK-1 isoform in liver, as besides 
contributing to the downregulation of insulin signalling, it plays a role in gluconeogenesis, 
lipogenesis and clearance of insulin from the systemic circulation (20).  
With regards to JNK in muscle tissue, Jnk-1 gene deficiency in this specific tissue does 
preserve the local insulin signalling, although systemically this effect is not widespread 
and is not strong enough to counterbalance the resistance in other tissues, it solely 
mitigates the issue. Moreover, mice in these experiments showed increased 
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hypertriglyceridemia due to reduction on muscle lipoprotein lipase, macrophage infiltration 
in adipose tissue and hepatic steatosis (21).  
Although liver, adipose tissue and muscle are major targets of the JNK pathway, it has 
important roles in other systems as well. In pancreatic β-cells, JNK also promotes insulin 
resistance, which leads to failure of insulin secretion. In this regards, JNK activation in 
pancreatic β-cells blocks the second phase of glucose-triggered secretion of insulin, which 
depends on IR signalling. It might also be involved in the pancreatic β-cells failure. (22).  
Finally, it is worth noticing that JNK is also important in the central nervous system as 
shown by the double Jnk-1- and -2-deficient mice, which die during development due to 
massive neuronal apoptosis. 
From all the recent discoveries and with more research being done every day, the JNK 
pathway presents a promising target for treating insulin resistance and type 2 diabetes 
because of its role in the regulation of insulin sensitivity. But as this is a complex system 
and JNK has different roles, developing efficient medications will not be an easy task, and 
tissue-specific medications might be required.  
 
1.5. Role of Protein Phosphatase 5 in Insulin Resistance 
Protein phosphatase 5 (Pp5) is a serine/threonine phosphatase and a member of 
phosphoprotein phosphatase (PPP) family, which also includes Pp1, Pp2A and Pp2B. 
Although it is a part of a family of proteins, the similarity of Pp5 to the other members is 
relatively low (23). Two unique domains that are present only in Pp 5 and not in other 
members of the PPP family are a peptidyl-prolyl cis-trans isomerase-like domain and three 
consecutive tetratricopeptide repeat (TPR) domains at the N-terminal region. The latter 
domain is present in other proteins that interact with Heat Shock Protein 90 (HSP90), a 
protein with a well-known function of controlling the early steps in steroid receptor 
activity among others. 
Pp5 is involved in numerous cellular functions, including cell proliferation, migration, 
differentiation, electrolyte balance, apoptosis and DNA repair, expressed in virtually all 
mammalian tissues and broadly distributed within the cells as well (24). It is expressed and 
activated in response to ROS, a condition that coincidentally occurs in obesity. 
Pp5 might have an important role in the early stages of insulin resistance development, 
with numerous studies being conducted to explore its role. One group of researchers 
experimented with genetically disrupted Pp5 mice which were fed with a high-fat diet 
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(HFD) and showed that, although the caloric intake between the wild type (WT) and knock 
out (KO) mice were similar, the Pp5 deficient mice gained less weight and did not 
accumulate visceral body fat compared to their WT counterparts. After 10 weeks on HFD, 
Pp5-deficient mice showed glucose control similar to the one of WT mice on the standard 
diet (SD). Furthermore, the Pp5-deficient mice on SD displayed better glucose control than 
the WT group (25). It is theorised that this occurs because Pp5 has an important role in the 
MAPK signalling pathway. In this theory, a key role is played by apoptosis signal-
regulating kinase (ASK1). This is a mammalian MAP3K and is activated by various 
cytotoxic stresses, like H2O2, and inflammatory signalling molecules, like TNF-α. Once 
ASK1 is activated, it transfers the signal downstream to the next kinase in this signalling 
pathway, MKK7, and through it, JNK is activated, a kinase that we previously discussed, 
plays a major role in the development of insulin resistance and consequent type 2 diabetes. 
It was discovered that Pp5 interacts directly with the AKS1, and further experiments 
showed that Pp5 inhibits ASK1 activity (26). Furthermore, the same experiments showed 
that Pp5 inhibits AKS1 in the negative feedback manner and inhibits ASK1-depended 
apoptosis. As ASK1 connects Pp5 to the JNK, a kinase that we already know has an 
important role in the obesity-induced insulin resistance, this pathway became a point of 
interest for researchers to examine possible ways of modifying it as a mean to treat type 2 
diabetes, with some encouraging discoveries being made, as by activating Pp5 signalling 
pathway, the JNK signalling is inhibited and with this insulin resistance might be blunted. 
However, there is some conflicting evidence in the role that Pp5 plays in the development 
of insulin resistance. Mice with inactivated Pp5 exhibited decreased size of adipose tissue 
when compared to the WT group, with knock-out mice also showing raised levels of 
glucocorticoids and hyperphosphorylation of glucocorticoid receptors (27).   
Glucocorticoids, like endogenous cortisol, exert their functions by binding to specialised 
glucocorticoid receptors (GR). When these receptors are activated by hormone binding, 
they translocate from the cytoplasm into the nucleus where they bind to glucocorticoid 
response elements, resulting in the regulation of gene expression. Glucocorticoids promote 
the expression of anti-inflammatory proteins like glucocorticoid-induced leucine zipper, 
interleukin (IL)-10, and inhibit the expression of inflammatory genes, like IL-1, -2, -3, -4, -
5, -6 and -8. But the immune system is not the only target, as these hormones also 
substantially impact metabolism, with stimulation of fat breakdown possibly being a useful 
effect in combating against insulin resistance, although this might not be as useful as other 
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alternatives, as gluconeogenesis and lower glucose intake of the tissues are also some of 
the effects glucocorticoids cause. 
One important protein that is involved in the glucocorticoid signalling is the previously 
mentioned HSP90, a protein that also is a binding target of Pp5’s TPR region, and through 
it, a possible way for Pp5 to influence this pathway. A study showed that the Pp5 
influenced the pathway in an inhibitory way, as a theory was made that the phosphatase 
keeps the GR in a dephosphorylated state, and thus inactive. Mice with inactivated Pp5 
exhibited less weight gain and improved glucose tolerance and insulin sensitivity when 
compared with WT counterparts on an SD. HFD results were not so unambiguous, as Pp5 
deficient mice on 10 weeks of HFD exhibited lower weight gain and better glucose 
tolerance (27), while the subjects on 20 weeks of HFD displayed opposite results, with 
more weight gain and worse glucose tolerance, when comparing to WT animals under the 
same conditions (27). Despite that, the possible effect Pp5 has on glucocorticoids cannot 
be ignored and potentially it can have a major impact. 
Although the exact role of Pp5 in obesity-induced insulin resistance is still a matter of 
controversy, it is clear that it does play a major part in the development of it due to its 
effects on immune system and inflammation, and as it potentially is a brand new pathway 
through which antidiabetic medications could work, so its role in type 2 diabetes should be 
explored. 
 
1.6. Liver X Receptors, Glucose Transporter Type 4 and GW3965 
Liver X receptors (LXRs) are nuclear receptors that are highly expressed in metabolically 
active tissues and cells of the immune system and are engaged in regulation of genes 
involved in cholesterol catabolism and transport, lipid and triglyceride biosynthesis and 
carbohydrate metabolism, as well as regulation of inflammatory gene transcription (28).  
Two isoforms of LXR have been discovered, LXRα and LXRβ. While the α isoform is 
highly expressed solely in the liver, adipose tissue, small intestine and macrophages, the β 
isoform is expressed ubiquitously (28). Some ligands bind to both isoforms, with 
oxysterols representing the endogenous agonists (29). LXRs carry out their role of 
regulation of target gene expression through direct binding to LXR-responsible elements in 
the genome, as heterodimers with retinoid X receptors (RXR). When ligand-binding 
occurs, a conformation change in the LXR releases the corepressors present in the 
complex, recruits coactivators and target genes are transcribed (Fig. 5). Another 
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mechanism of action independent of the direct interaction on the DNA, known as 
transrepression, is possible for the gene transcription regulation and primarily used by β 
isoform. Here LXR strongly inhibits the transcription of NF-kB-regulated proinflammatory 
genes, and when the receptor undergoes a conformation change due to ligand binding and 
interaction with a repressor of gene transcription is promoted. With this mechanism, LXR 
blocks the transcription of proinflammatory genes (28).  
 
Figure 5: Gene expression through LXR. Adapted from (28). (LXR – liver X receptor; RXR - retinoid X 
receptor). 
As genes like ABCA1, ABCG1, APOE, CYP7A and others are involved in lipid metabolism 
and cholesterol transport and are regulated by LXRs, possible involvement of these 
receptors in diabetes was proposed. In addition to well-known LXR target genes, the 
functional genomic analysis showed that the expression of Pp5 was activated in response 
to LXR-ligand administration and in an LXR-dependent manner in mice (30). Researchers 
carried out experiments with diabetic rodents, which were treated with an agonist of LXRs. 
Results that were obtained displayed a dose-dependent lowering of plasma glucose levels 
in the animals that were treated with the agonist, with increased levels of plasma and liver 
triglycerides and no change in plasma insulin levels measured (31). Moreover, obese mice 
that were treated with the LXR agonist showed a significant improvement in glucose 
tolerance, with normal animals displaying no changes in the glucose levels, which led 
researchers to hypothesise that LXR agonist lower glucose levels solely in animals that 
already have developed insulin resistance, and do not affect healthy ones (31). 
The underlying mechanism that seems to be responsible for this effect is the inhibition of 
gluconeogenesis. Significant reduction in the mRNA levels of PEPCK 
(phosphoenolpyruvate carboxykinase) and G6PC (glucose-6-phosphatase), two genes that 
encode key gluconeogenesis enzymes, were observed in animals treated with the LXR 
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agonist (31). When the transcription of these genes is hindered, hepatic gluconeogenesis 
pathway is inhibited and thus less glucose is synthesised and released from the liver into 
the systemic bloodstream. Additionally, due to the importance of inflammation in 
promoting insulin resistance, the anti-inflammatory action of LXR might also be an 
important action for the insulin-sensitizing effects of its agonists. 
But one of the main ways LXR affect the carbohydrate metabolism is the receptor’s effect 
on a protein that facilitates the transport of glucose, called glucose transporter type 4 
(GLUT4). This transporter is one of the 13 sugar transporters present in the human 
genome, which belong to the major facilitator superfamily (MFS) (32). This transporter is 
expressed in numerous tissues, including liver, muscle and fatty tissues, and is encoded by 
the Slc2a4 gene. Although other transporters do appear in these tissues and in other parts of 
the human body, GLUT4 has relatively unique trait where it is located - mostly in the 
cytoplasm and is only translocated to the cell membrane when the translocation is 
stimulated. Once in the membrane, 12 helices transverse through the lipid layer of the cell 
membrane, forming glucose transport channel, and thus catalyse ATP-independent 
substrate transfer across the membrane (33). Expression and translocation of GLUT4 
storage vesicles (GSV) can be stimulated by different factors, with two main being 
physical exercise and, more importantly, insulin. Insulin affects the translocation of the 
transporter to the cell membrane in a couple of ways (Fig. 6). Firstly, when the IR is 
activated, it causes the phosphorylation of IRS proteins, which then become docking sites 
for the recruitment and activation of PI3K. This kinase causes the further phosphorylation 
of substrates and thus forms PIP3, a molecule that recruits PDK1 and AKT. AKT, through 
PDK1 and with the help of mammalian target of rapamycin complex 2 (mTORC2), is 
activated and can then phosphorylate GTPase-activating proteins – AS160 (regulates 
vesicle translocation) and RGS (regulates vesicle targeting). This inactivates them, and this 
causes the exocytosis of the GLUT4 (34). Additionally, IR activation also causes 
recruitment of adaptor protein CRK and guanine nucleotide exchange factor (GEF), 
culminating in the activation of GTPase TC10. TC10 interacts with the exocyst complex, 
creating targeting sites for the GLUT4 containing vesicles at the cell membrane (34). With 
these two signalling cascades, insulin causes the intake of glucose through GLUT4, thus 
completing one of its most important roles. 
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Figure 6: GLUT4 exocytosis mediated through AKT. Adapted from (34). (PI3K - phosphoinositide 3-
kinase; PDK1 - phosphoinositide-dependent protein kinase-1; mTORC2 - mammalian target of rapamycin 
complex 2; RCG - RaL GAP complex; AS160 - Akt substrate of 160 kDa; GSV - GLUT4 storage vesicles). 
What researchers have found is that LXR, more precisely the α isoform, are involved in 
GLUT4 expression and its exocytosis. They discovered that when the cells were treated 
with a PPARγ agonist, this also increased the expression of LXRα, and with it, an increase 
in GLUT4 expression also occurred. How this happens, is currently unknown, but it is 
theorised that LXR heterodimer binds to a GLUT4 promoter region, which contains 
conserved DR-4 type LXRE. This promotes the transcription of the Slc2a4 gene, and thus 
GLUT4 is expressed, causing the increase of glucose intake into the cell (35). 
 
Although not the primary focus of our research, this pathway could have an important role 
in diabetes treatment in the future, hence we decided to carry out some experiments with 
LXR agonist designated GW3965 (Fig. 7). This is a non-steroidal agonist of both α and β 
isoforms of liver X receptors, and its actions and effects are almost completely identical to 
the ones we described in the text above, thus showing a potential use for the treatment of 
diabetes. 
With the use of X-ray crystallography researchers were able to deduce which moieties of 
the GW3965 agonist are essential for forming interactions with the LXR, with 4 distinct 
cavities in the receptor structure presenting interaction sites (36). From these experiments, 
the chloro-trifluoromethylbenzyl moiety, diphenylethyl moiety and the acetic acid 
elements of the GW3965 are crucial for the binding of the molecule to the LXR and 
provide a good base on which next generations of molecules can be developed. It is worth 
noting that the same interactions were observed in both the α and β isoforms of the liver X 
receptors (37), indicating that if the need for subtype-specific compounds will be needed, 
the development of such molecules will be a major obstacle. 
17 
 
 
 
Figure 7: GW3965 structure 
Although these experiments showed that LXR agonists like GW3965 have the potential to 
become novel drugs for the treatment of diabetes, and in the future may represent an 
important antidiabetic group of medications, quite a few obstacles have to be overcome 
before that becomes possible. One of the major stumbling blocks currently is that agonists 
of these receptors induce hypertriglyceridemia and liver steatosis, thus selective 
modulators of LXRs will have to be developed before their therapeutic use is possible.   
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2. Aim of Work 
As discussed in the Introduction section, different mediators are affecting insulin signalling 
and play different roles in diet-induced obesity, together causing the development of 
insulin resistance, which subsequently progresses into type 2 diabetes. The aim of our 
work is to study the effects of different physiological mediators in diet-induced obesity and 
insulin resistance. We are interested in the interaction of JNK and Pp5, among others, 
involved in this process, and aim to explore whether they play a protective role, or do they 
affect it negatively. Furthermore, we are also interested in how Pp5 affects these processes 
and whether it has any impact on the disease. We will analyse the expression of these 
particular mediators in mice and quantify their levels with different methods in 3 different 
tissues: liver, skeletal muscle and white adipose tissue. Mice will be divided into 2 groups, 
with one being fed with HFD, while the other group will be on SD. Half of the number of 
the mice will be genetically modified, as they will have Pp5 gene inactivated, thus 
enabling us to see the influence of this protein on the insulin resistance. Additionally, since 
Pp5 is an LXR-target gene we will analyse what kind of an effect does an LXR agonist 
GW3965 have on the insulin-sensitizing and if so, if this is mediated by Pp5, and if this 
type of molecules could provide a new group of medications for the therapy of diabetes. 
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3. Materials and Methods 
3.1. Materials 
During the execution of this project, the following materials and equipment have been 
used: 
3.1.1. Laboratory Equipment 
Equipment Model and Maker 
Analytical scale Sartorius CP 2245, Sartorius, Germany 
Fume hood VA090810/960, Flores Valles, Spain 
Autoclave AA20-HT, LABEC, Australia 
Automatic pipettes 0,2-2; 2-20; 10-100; 
100-1000 µL 
Pipetman, different models, Gilson, USA 
Centrifuge tubes 1,5 mL 
Eppendorf Tubes® 3810X, Eppendorf, 
Germany 
Centrifuge tubes 15 and 50 mL 
Corning® 15 mL and 50 mL PP 
Centrifuge Tubes, Corning, USA 
Centrifuges 
Eppendorf 5415R centrifuge, Eppendorf, 
Germany 
X-ray developing machine 
Kodak Medical X-Ray Processor 102, 
Kodak, USA 
Horizontal electrophoresis chamber 
Wide Mini-Sub Cell GT Cell, Bio-Rad, 
USA 
Vertical electrophoresis chamber 
Mini-PROTEAN® Tetra Vertical 
Electrophoresis Cell, Bio-Rad, USA 
Gel imagining instrument 
Gel Doc™ EZ Gel Documentation System, 
Bio-Rad, USA 
Gel Transfer Device 
iBlot™ 2 Gel Transfer Device, Thermo 
Fisher Scientific, USA 
Glass pipettes of 5, 10, and 25 mL 
Westlab graduated pipette, different 
volumes, Australia 
Heat block Grant UBD2, PROLABMAS, Indonesia 
Homogeniser 
POLYTRON® Immersion Disperser 
PT2100, Kinematica, Switzerland 
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Magnet for the magnet mixer Magnetic Stirring Bar, Glassco, India 
Magnetic mixer 
PMDC Magnetic Mixer, FLUIDYNE 
INSTRUMENTS PVT. LTD, India  
PCR instrument 
GeneAmp PCR System 9700, Thermo 
Fisher Scientific, USA 
Plastic pipettes of 5, 10, and 25 mL 
Greiner CELLSTAR® serological pipette, 
different volumes, Greiner Bio-One 
International GmbH, Austria 
Power supply 
PowerPac Universal Power Supply, Bio-
Rad, USA 
Precise pipette controller for glass and 
plastic pipettes 
Macroman F110120, Gilson, USA 
Quantitative PCR instrument 
QuantStudio 3 Real-Time PCR System, 
Thermo Fisher Scientific, USA 
Shaker DOS-20L, Elmi, USA 
Spectrophotometers 
 
NanoDrop® ND-1000 Spectrometer, 
Thermo Fisher Scientific, USA 
UV mini 1240, Shimadzu, Japan 
Rotator Rotamix Rotator, ATR, USA 
Vortex mixer ISG Vortex Mixes, Westlab, Australia 
Water bath 
WBL-10LC-SSD1 Water Bath, LW 
Scientific, USA 
 
3.1.2. Chemicals and Media 
Chemicals Supplier 
Bis-acrylamide 40% solution Bio-Rad, USA 
Agarose Sigma-Aldrich, USA 
Ammonium persulfate (APS) Sigma-Aldrich, USA 
B-glycerophosphate Sigma-Aldrich, USA 
Bradford reagent 
Bio‐Rad Protein Assay Dye Reagent 
Concentrate 5X, Bio-Rad, USA 
Bromophenol blue Sigma-Aldrich, USA 
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Chloroform Sigma-Aldrich, USA 
Dithiothreitol (DTT) Sigma-Aldrich, USA 
EDTA Sigma-Aldrich, USA 
EGTA Sigma-Aldrich, USA 
Ethanol PanReac, USA 
Ethidium bromide Sigma-Aldrich, USA 
Glucose Sigma-Aldrich, USA 
Glycerol Sigma-Aldrich, USA 
HEPES Sigma-Aldrich, USA 
Isopropanol PanReac, USA 
Methanol PanReac, USA 
MgCl2 Sigma-Aldrich, USA 
Fat-free milk Central Lechera Asturiana, Spain 
Na3VO4 Sigma-Aldrich, USA 
NaCl Scharlab, Spain 
NP-40 Sigma-Aldrich, USA 
PBS Sigma-Aldrich, USA 
PMSF Sigma-Aldrich, USA 
SDS Sigma-Aldrich, USA 
TEMED Sigma-Aldrich, USA 
Tris Scharlab, Spain 
TWEEN® 20 Scharlab, Spain 
 
3.1.3. Sets 
Set Name and Supplier 
Concentrated solution of the components 
for qPCR 
PCR MASTER MIX 2X, Thermo Fisher 
Scientific, USA 
Taq DNA polymerase kit DNA Polymerase 1U/µL, Biotools, Spain 
dNTPs mix Biotools dNTPs mix, Biotools, Spain 
Horseradish peroxidase (HRP) substrate 
for enhanced chemiluminescence (ECL) 
Pierce™ ECL Western Blotting Substrate, 
Thermo Fisher Scientific, USA 
PCR Buffer 10X GeneAmp 10X PCR Buffer Applied 
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Biosystems 
DNA polymerase Biotools, Spain 
Reverse transcriptase Invitrogen 
 
3.1.4. Antibodies Against the Following Antigens 
Antibody Supplier 
Mouse p-AKT Abcam, UK 
Rabbit AKT Santa Cruz Biotechnology, USA 
Mouse p-JNK Merck Millipore, USA 
Mouse JNK Santa Cruz Biotechnology, USA 
Mouse Pp5 BD Biosciences, USA 
Mouse Actin Roche, Switzerland 
Monoclonal anti-mouse antibody 
conjugated with horseradish peroxidase 
Jackson ImmunoResearch Labs, USA 
Monoclonal anti-rabbit antibody 
conjugated with horseradish peroxidase 
Jackson ImmunoResearch Labs, USA 
 
3.1.5. Proteins 
Peptides and Proteins Supplier 
Aprotinin Sigma-Aldrich, USA 
Bovine serum albumin (BSA) Sigma Aldrich, USA 
Leupeptin Sigma-Aldrich, USA 
 
3.1.6. Buffers, Solutions and Gels 
3.1.6.1. Protein Lysis Buffer is a solution used to obtain the tissue extract. A stock 
solution was prepared (Table II) and then kept at the temperature of 4 ºC until use. 
Components shown in Table III were added immediately before use and the final solution 
was kept on ice during its use. 
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Table II: Stock lysis buffer 
Components Volumes 
Hepes buffer (pH=7,5) 1 M 1 mL 
MgCl2 1 M 0,125 mL  
EGTA 500 mM 1 mL      
Β-glycerophosphate 500 mM 4 mL   
NP-40 100% 0,5 mL   
mQ H2O Up to final volume of 50 mL  
 
Table III: Working lysis buffer 
Components Volumes 
Na3VO4 200 mM 100 µL  
DTT 1 M 10 µL 
PMSF 100 mM 100 µL 
Aprotinin 10 mg/mL 1 µL 
Leupeptin 10 mg/mL 1 µL 
Stock solution Up to final volume of 10 mL 
3.1.6.2. Sodium Dodecyl Sulphate–Polyacrylamide Gels are a type of gels used for the 
electrophoretic separation of proteins. Sodium dodecyl sulphate (SDS) is added as it acts as 
a surfactant and therefore denatures the proteins, and homogenously charges them 
negatively, therefore proteins separate depending solely on their molecular weight. We 
used a discontinuous system, where we prepared gels which included top, stacking gel, 
which enables proteins to amass closely together and in turn, we achieve better resolution, 
and bottom, resolving gel. Depending on the molecular weight of the target proteins, 
suitable acrylamide percentage of the gel is chosen. In our case that was a 10% (Table IV) 
resolving gel, while the stacking gel was 5% (Table V). Given volumes were required for 
the preparation of 4 SDS-polyacrylamide gels, as the majority of times that was the 
required number of gels to run the samples.  
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Table IV: Resolving gel 
Components Volumes 
Tris buffer 1,5 M, pH=8,8 7,5 mL  
Acrylamide 40% 7,5 mL  
SDS 10% 0,3 mL  
APS 10% 0,3 mL   
TEMED 0,012 mL 
mQ H2O 14,388 mL 
Table V: Stacking gel 
Components Volumes  
Tris buffer 1 M, pH=6,8 1,5 mL  
Acrylamide 40% 1,5 mL  
SDS 10% 0,12 mL  
APS 10% 0,12 mL   
TEMED 0,012 mL 
mQ H2O 8,748 mL 
3.1.6.3. Sample Buffer is a solution used for loading of protein samples into SDS-
polyacrylamide gel. It provides denaturing conditions and negative charge for proteins, as 
well as increases the relative density of the sample for loading. The composition of the 
sample buffer is shown below (Table VI). 
Table VI: Sample buffer 
Components Amounts 
Tris 1 M, pH=6,8 2 mL   
Glycerol 4 mL  
SDS 0,8 g 
DTT 0,6172 g 
Bromophenol blue 0,04 g 
mQ H2O Up to final volume of 10 mL   
3.1.6.4. Tris-Glycine Buffer is a solution which is used as a running buffer in SDS-
PAGE. The composition of the buffer shown below (Table VII) is equivalent to a 5× 
concentrated solution and needs to be diluted with water before use.  
Table VII: Tris-glycine buffer 
Components Amounts 
Tris base 30,2 g 
Glycine 188 g 
SDS 10% 100 mL  
mQ H2O  Up to final volume of 2 L 
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3.1.6.5. Transfer Buffer is a solution used in the process of transferring resolved 
proteins from SDS-PAGE to PVDF membranes. The composition of the buffer is shown 
below (Table VIII). 
Table VIII: Transfer buffer 
Components Amounts 
Tris base 17,4 g 
Glycine 8,7 g 
SDS 1,11 g 
Methanol 600 mL   
mQ H2O  Up to final volume of 3 L 
3.1.6.6. TBS-Tween®20 (TBS-T) We used this buffer for washing the PVDF membranes 
in the immunoblotting procedure, to reduce the background. First, we prepared a TBS 
stock solution, which was 10× concentrated (Table IX), and that stock solution was used to 
immediately before use to prepare final TBS-T buffer (Table X).  
 Table IX: 10x TBS stock solution                                                    Table X: Working TBS-T buffer                                                         
Components Volumes 
Tris-HCl 1 M, pH=7,4 200 mL  
NaCl 87,7 g 
mQ H2O 
Up to final 
volume of 1 L 
3.1.6.7. Tris-Acetate EDTA (TAE) Buffer used in electrophoresis of nucleic acids in 
agarose gels. It contains EDTA, a chemical that acts as a chelating agent and protects the 
DNA from hydrolysis during the migration through the agarose gel. The composition of 
the buffer shown below (Table XI) is for the preparation of 50× concentrated solution, 
which was diluted with water before use.  
Table XI: 50X TAE buffer 
Components Amounts 
Tris base 242 g 
Glacial acetic acid 57,1 mL    
EDTA 0,5 M, pH=8,0 100 mL    
mQ H2O Up to final volume of 1 L 
Components Volumes  
TWEEN®20 500 µL 
TBS 10× 50 mL   
mQ H2O 
Up to the final 
volume of 500 mL 
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3.1.6.8. Agarose Gels Agarose gel is used in the electrophoresis of nucleic acids. It is 
used as a diagnostic tool to help visualize fragments of nucleic acids, as they migrate 
through the gel and are separated depending on their mass. For RNA and PCR-generated 
DNA fragments, we used 1% (Table XII) and 2% (Table XIII) agarose gels, respectively. 
Given amounts are sufficient for the preparation of bigger size of the gels, but if the 
smaller size was adequate, the amounts were halved.  
Table XII: 1% agarose gel 
Components Amounts 
Agarose 1 g 
Ethidium Bromide 2 mg/mL 25 µL  
TAE Up to 100 mL  
Table XIII: 2% agarose gel 
Components Amounts 
Agarose 2 g 
Ethidium Bromide 2 mg/mL 25 µL 
TAE Up to 100 mL  
 
3.2. Methods 
During the execution of this project, the following methods were used: 
 
3.2.1. The Basis of the Experiment 
24 4-week-old wild-type male house mice (Mus musculus) and 24 4-week-old Pp5-
knockout (KO) male mice were split into two groups fed an HFD or SD ad libitum for 10 
weeks. During this time, weight data was collected once per week. Pp5-knockout was 
accomplished by deleting the exon that encodes the catalytic region of the protein. 15 days 
prior to sacrifice, HFD groups were challenged intraperitoneally with a daily dose of 20 
mg/kg of LXR ligand GW3965 dissolved in carboxymethyl cellulose (CMC) or CMC as 
vehicle alone. Given the aim of the experiment, the SD group was not treated at any point 
because it did not present any kind of insulin insensitivity. On days 10 to 12 of treatment, 
glucose tolerance test (GTT) and insulin tolerance test (ITT) were performed. In GTTs, 
subjects were fasted for 6 hours and then injected intraperitoneally with a dose of 2 g/kg of 
glucose. Blood was collected from the tail vein at the indicated time points and glucose 
levels were measured with an automatic glucometer. Concordantly, ITTs were carried out 
after 6 hours of fasting, the process being quite similar to the GTT. Here, the mice were 
administrated a dose of 0,5 IU/kg of insulin and blood was also collected from the tail vein 
at the indicated time points and glucose levels were measured with an automatic 
glucometer. 15 minutes before scarification, half of the mice were injected with the same 
concentration of insulin as it was used for ITT. On the last day of treatment, mice were 
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anaesthetized in an isoflurane chamber with a dose of 3% isoflurane and 3,5 L/min O2 and 
heart puncture was carried out, with blood being collected with this process. Afterwards, 
muscle, liver and epididymal white adipose tissues were collected and stored at -80ºC for 
further analysis. 
 
3.2.2. Protein Extraction from Tissues 
Tissue samples, which were kept at -80 ºC, were transported in an insulating box 
containing dry ice. We added 500 µL of freshly prepared final lysis buffer (section 3.1.6.1) 
into a 2 mL centrifuge tube. We cut a piece of the frozen tissue and transferred it into the 
tube with lysis buffer. From now on, samples were manipulated at 4˚C. For the 
homogenisation of tissues, we used Polytron Homogenizer with an appropriate probe, 
which was washed with PBS before and after use. We disaggregated the tissue, with tissue-
specific times needed for appropriate homogenisation. When all the samples were 
processed, we centrifuged them at 13000 rpm for 15 minutes at 4 ºC. In the case of muscle 
and liver samples, one round of centrifuging was adequate, and we transferred the 
supernatant into a new 1,5 mL centrifuge tube. In the case of white adipose tissue, another 
round of centrifuging was needed, as we observed floating impurities, mostly fat. 
 
3.2.3. Determination of Protein Concentration 
The concentration of each individual sample was measured with the Bradford method. 
Bradford reagent requires a 5-fold dilution before use. For the procedure, we also needed 
to prepare a calibration curve. In 7 microcentrifuge tubes we dispensed 1 mL of the diluted 
Bradford reagent, and then added different amounts (none, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg 
and 12 mg) of BSA protein. Each of the prepared solutions was transferred into a cuvette 
and with the use of a spectrophotometer, we measured absorbance at 595 nm. Acquired 
data was subsequently processed with a computer to obtain the calibration curve. Next, we 
prepared new tubes for the samples. Into each individual tube, we again dispensed 1 mL of 
the Bradford reagent and added 2 µL of the protein extract sample. We used a vortex to 
mix the sample and the reagent, and then determined the absorbance at 595 nm. With the 
previously obtained calibration curve, we calculated the concentrations of the samples, and 
with this data, we diluted all the samples to the same final concentration of 2 µg/µL. 
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3.2.4. Immunoblotting 
This was a process that included the following steps. 
3.2.4.1. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis First step we 
took was the preparation of the Sodium Dodecyl Sulphate Polyacrylamide Gels (section 
3.1.6.2) and, depending on the number of samples we had and wanted to run, we prepared 
an adequate number of these gels. If the samples were run the same day, we put the SDS 
polyacrylamide gels inside of the electrophoresis chamber, which was filled with Tris-
Glycine buffer (section 3.1.6.4), but if the electrophoresis was done at a later time, these 
gels were preserved in a moist paper, wrapped in aluminium foil and stored at 4 ºC. Next, 
we prepared the samples for the application into the SDS polyacrylamide gels. New 
centrifuge tubes for each individual sample were prepared, and in those tubes, we 
dispensed 50 µL of previously diluted protein samples and 20 µL of loading buffer (section 
3.1.6.3). These mixtures were placed into a heat block and incubated for 5 minutes at 99 
ºC, which was followed up with a short centrifuging at 13000 rpm. Samples were now 
ready to be loaded into the gels (7 µL/well, which corresponded to 10 µg of protein), 
slowly releasing the content of the pipette, so no sample leaked into the neighbouring 
wells. Into the first and last well, we loaded 5 µL and 2 µL of an appropriate marker, 
respectively, so we could orient our gels and later membranes depending on the marker 
intensity.  
After sample loading, we topped-up the chamber with Tris-Glycine buffer to the 
appropriate mark on the chamber, so the SDS polyacrylamide gels were in the buffer and 
the electrical current could flow, and we started the electrophoresis. At first, while the 
samples were migrating through the stacking part of the gel, current of 30 mA was applied, 
but after they migrated into the resolving part of the gel, we increased the current to 60 
mA, as it enabled faster migration. After the loading buffer dye travelled to the bottom of 
the gel, the process was stopped, and the gels were taken out. 
3.2.4.2. Wet Transfer The next step in the immunoblotting process was the transfer of 
the now separated proteins from the gel and onto a PVDF membrane. We accomplished 
this in two ways, depending on the available equipment and materials. The first method 
included the use of a gel transfer device, which is a special piece of equipment that uses 
PVDF membranes in specially packaged sets, which are called stacks and are put in the 
machine, where the transfer takes place. For this operation, we cut the gels to the more 
appropriate size while being careful not cut the analysed proteins as well. These cut gels 
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are then put on the transfer membrane located in the aforementioned stacks. This package 
was put inside of the machine, covered with the conductive layer and the appropriate 
programme for our transfer was chosen from available presets. The transfer took 7 minutes 
to complete, after which we took the stack out of the machine, and disposed of the gels, 
which were now empty, and other parts of the stack, leaving only the membrane with the 
transferred proteins, and that membrane was put into TBS-T buffer (section 3.1.6.6) to 
prevent drying.  
The second method of protein transfer was using a transfer chamber and the transfer buffer 
(section 3.1.6.5). This method is more time consuming and we used it only when the other 
method was not available. Here, we transferred proteins on the same type of membrane as 
before, PVDF, only this time we had to cut the membrane out of a big sheet, and 
additionally, we cut Whatman paper which was needed for the process as well. In the 
cassette we put the following items, which were previously damped in the transfer buffer, 
in the following order (from the black side on the bottom): a Fiber pad, two Whatman 
papers, the PVDF membrane, the gel from the SDS-PAGE, two Whatman papers and a 
Fiber pad. We tightly closed the cassette and put it in the Transfer chamber, where it was 
submerged into the transfer buffer, to prevent the drying of the membrane. The orientation 
of the cassette in the chamber was of the utmost importance as if we put it the wrong way 
in, the proteins would travel away from the membrane and the transfer would have been 
unsuccessful. A small stirring magnet was put inside of the chamber, which was then 
placed on the top of the magnetic stirrer in the refrigerator at 4 ºC, at which point we 
connected the chamber to the power supply, that was set on 100 mA. To ensure the transfer 
was successful, we let it run overnight, and in the morning, we took the membrane out and 
put it in TBS-T buffer to prevent drying. 
3.2.4.3. Blocking and Antibody Incubation The first step of this process was blocking of 
the membranes, as this is an important step to prevent nonspecific binding of antibodies 
later. For this task, we prepared 5% solution of non-fat milk (for regular antibodies) or 5% 
of BSA (for anti-phospho specific antibodies), in TBS-T buffer. Membranes with the 
transferred proteins were put in small containers with 10 mL of the appropriated blocking 
solution. These containers were put on the shaker for 1 hour at room temperature.  
After the hour elapsed, it was time to apply the primary antibody. For this reason, we 
prepared small plastic bags, in which we put the membranes, and sealed all the ends of it, 
except one, through which we added 3 mL of desired primary antibody, which was 
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previously diluted 1000-fold with the TBS-T buffer. The last side was then sealed, and we 
put the plastic bag on the agitator, where we left it overnight at 4 ºC. In the morning we 
removed the membranes from the plastic bags and put them in small plastic containers, 
where the process of washing was executed. For this process, we used the TBS-T buffer, in 
which we put the membranes for 10 minutes, and repeated this procedure 3 times. Next, 
into the containers with membranes, we dispensed 7 mL of TBS-T and added 1 µL of the 
secondary antibody, which was conjugated with HRP. We left these containers on the 
shaker for 1 hour, and that was followed up with another round of washing with TBS-T, 
likewise 3 times for 10 minutes with approximately 10 mL of the buffer. When possible, 
we immediately proceeded with membrane development, but if not, the membranes were 
kept in TBS-T until processing. 
3.2.4.4. Membrane Development and Protein Detection 
Detection of proteins was based on the detection of a signal emitted by HRP-conjugated 
antibody. We mixed the 2 components of ECL in ratio 1:1 in a 15 mL falcon tube and 
poured the mixture into small plastic containers. For each membrane we had to develop, 
we needed 3 mL of the ECL mixture. Into the containers we placed the membranes, which 
were then gently shaken for 5 minutes, making sure that the whole membrane was covered 
by the solution. After 5 minutes elapsed, we placed the membranes into special cassettes. 
In a dark room, we placed an X-ray film on top of the membranes and the cassette was 
closed. The film was left to absorb the light which was being emitted by the product of 
HRP enzymatic reaction. We took the film out of the cassette and inserted it into the 
developing machine. On these films we draw the ladder bands from the marker, which we 
applied into the gel at the beginning of the electrophoresis, then we scanned these tagged 
films and analysed them with appropriate software for quantification purposes.  
 
3.2.5. RNA Extraction 
RNase-free conditions were met during and after the RNA extraction. 
We used the same tissue samples as we did for the protein extraction. Samples, which were 
kept at -80 ºC, were transported in an insulating box containing dry ice to the laboratory. 
For each sample, a 2 mL centrifuge tube filled with 400 µL of TRIzol reagent was 
prepared. We cut a piece of tissue using a scalpel and transferred it into the tube. Next, 
tissue samples were disaggregated and dispersed using Polytron homogeniser, with the 
same tissue-specific times needed just like in protein extraction. We added additional 200 
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µL of TRIzol reagent into each centrifuge tube, now containing homogenised tissue, and 
then placed these tubes into a centrifuge and centrifuged them for 15 minutes at 4 ºC and 
13000 rpm. Next, we transferred the lysate into a new set of 1,5 ml-centrifuge tubes. Under 
a fume hood, we added 100 µL of chloroform and mixed the tubes for 15 seconds using a 
vortex mixer. Tubes were left at room temperature for 3 minutes and then centrifuged for 
15 minutes at 4 ºC and 13000 rpm. We transferred the aqueous phase carefully, avoiding 
other floating particles, into new 1,5 mL centrifuge tubes, added 500 µL of isopropanol, 
and after a quick shake with hand, left them at room temperature for 10 minutes. Samples 
were centrifuged at 13000 rpm for 10 minutes at 4 ºC, and the supernatant was carefully 
removed with the help of a pipette, leaving just the pellet in the tube. Pellets were washed 
with 500 µL of 80% ethanol, centrifuged for 5 minutes at 7500 rpm and ethanol was 
carefully removed. Pellets were air-dried under the laminar flow hood, and once there were 
no visible liquid drops, dissolved in 15 µL of RNase-free water. Finally, samples were 
incubated at 55 ºC for 10 minutes, and if not immediately needed, stored in the freezer at -
80 ºC. 
 
3.2.6. RNA Quantification 
After the extractions, we needed to measure the concentration and purity of the extracted 
RNA samples, and for fast and accurate measurements, we used a Nanodrop 
spectrophotometer. We used OD rations 260:280 nm and 260:230 nm to determine the 
purity of our samples. Preferred values for RNA OD ratios were 1,8 for 260:280 ratio, and 
2,0-2,2 for 260:230 one.  
Before the process of quantification could begin, we had to prepare the spectrophotometer, 
more precisely we had to clean the upper and lower optical surfaces, add 2 µL of mQ H2O 
and close the arm. With few taps on the arm, we cleaned the optical surface, and after a 
wipe, it was ready to be used. On the computer connected to the spectrophotometer we 
opened appropriate software, selected the mode for Nucleic acid measurement and chose 
RNA analysis. Before the first sample measurement, initialization was needed, and it was 
done by placing 2 µL of mQ H2O onto the lower optical surface, then we lowered the top 
arm, and clicked “INITIALIZE”. After this step, we cleaned both optical surfaces, added 2 
µL of mQ H2O and performed a blank measurement. Optical surfaces were cleaned again, 
and we loaded 2 µL of the sample, which was in turn measured and the concentration and 
the OD ratios were saved by the machine. After we cleaned both optical surfaces, the 
32 
 
described steps were followed for all the rest of the samples, and afterwards, data were 
transferred to a computer for later processing.  
 
3.2.7. RNA Electrophoretic Analysis 
For further experiments of gene expression analysis, it was paramount that the tissue-
extracted RNA was intact. RNA integrity was assessed by agarose gel electrophoresis 
(section 3.1.6.8). If RNA was not degraded, the RNA samples were resolved in 2 sharp 
bands corresponding to the ribosomal RNA 18S and 28S. However, if the degradation did 
occur, there were no clear lines but a blur along the line where the sample was migrating.  
We prepared the gels with 1% concentration of agarose, and depending on the number of 
samples we ran, we prepared a bigger or smaller version of the gel. Next, we prepared the 
samples: into small 200 µL tube, we mixed 5 µL of glycerol, 5 µL of RNase-free water, 
0,5 µL of sample RNA and mixed the solution with the help of a pipette. Samples were 
then loaded into the wells in the gel, placed in electrophoresis chamber, submerged in TAE 
buffer (section 3.1.6.7). Conditions (the current chosen for the electrophoresis) were 
dependant on the size of the gel; 80 mA and 120 mA were applied for smaller and larger 
gels, respectively. After the samples migrated a certain distance, we stopped the 
electrophoresis and took the gel out of the chamber and placed it into the gel imaging 
system to analyse it.  
 
3.2.8. Reverse-Transcriptase Quantitative Polymerase Chain Reaction (RT-qPCR) 
This technique is used to exponentially amplify specific fragments of DNA with the 
employment of a heat-stable form of DNA polymerase (Taq DNA polymerase). PCR relies 
on thermal cycling process, where the temperature fluctuates between different, pre-set 
values. The process starts with heating up the samples to 98 ºC, as at this temperature 
double-stranded DNA denatures. Temperature is then lowered to approximately 50 ºC 
(depends on the primers), which enables binding of the oligonucleotides. For the next step, 
an increase in temperature is needed, as the next step involves Taq DNA polymerase, 
which is optimally active at 72 ºC. This enzyme is a key ingredient in the PCR process, and 
it is of most importance it is thermoresistant, so the temperature cycles do not affect it. For 
both strands of the DNA, primers, short single-stranded nucleic acids, are prepared, as for 
Taq DNA polymerase to start replicating the DNA sequence. These primers are carefully 
constructed, so the replication can be done, and they are prepared for both sense and anti-
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sense DNA strands. Once primers bind to the targeted DNA, and DNA polymerase binds 
to this double helix structure, it uses the deoxynucleotide triphosphates or dNTPs, which 
are present in the mix, to multiply the DNA. 
In our case, we used PCR as a way to test the quality of the reverse transcription. For this, 
we decided to amplify the gene for β-actin, a gene that is used as a reference gene, as it is 
constitutively expressed in all the cells, regardless of the pathophysiological conditions. 
We used the same primers as we did for the RT-qPCR (section 1). 
We started the process with the preparation of samples. Into individual, 200 µL PCR tubes, 
we mixed 2 µL of cDNA, 2 µL of PCR Buffer 10X, 1,5 µL of 4 mM MgCl2, 3 µL of 
forward and reverse primers each, both at 2 µM, 0,2 µL of Taq DNA polymerase (5 
UI/µL), 0,8 µL of 20 mM dNTPs and we filled the mixture up to 20 µL with mQ H2O. 
Reaction tubes were then placed into the PCR machine, where we set up a programme, we 
closed the tray and started the process. When the amplification was finalised, we took the 
samples from the machine and loaded them into 2% agarose gels, where we conducted the 
process of electrophoresis. We left the DNA migrating up to a certain point, where we 
stopped the process, took the gel out of the chamber and placed it into the gel imaging 
system, where the DNA was analysed. If the process of reverse transcription was 
successful, we detected a clear band of the expected size. 
3.2.8.1. Reverse Transcription Is an advantageous technique that allowed us to generate 
first-strand complementary DNA (cDNA) from an RNA template. This was achieved with 
the use of a reverse transcriptase (RT) enzyme. From the data acquired with the 
spectrophotometer, we calculated the volume of our samples that contained 1 µg of RNA, 
mixed it with 1 µL of 100 mM random hexamers and RNase-free water in a centrifuge 
tube, to a final volume of 12,5 µL. These tubes we incubated for 5 minutes at 65 ºC, which 
we followed up with another incubation, this time at room temperature for 10 minutes. 
Next, into each reaction tube, we added 7,5 µL of the following mix: 4 µL of RT Buffer 
5X, 2 µL of 1 M DTT, 1 µL of 40 mM dNTPs (10 mM of each) and 0,5 µL of RT enzyme 
(200 U/µL). Tubes with the mix were incubated in a water bath at 37 ºC for 1 hour, and as 
the last step of the process, were put into a heat block, where we incubated them for 5 
minutes at 90 ºC.  
If newly synthesised cDNA was needed immediately for qPCR, we proceeded immediately 
with the method, otherwise, the samples were stored at -20 ºC.  
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3.2.8.2. Primers for Quantitative PCR Analysis Primers are short, single-stranded DNA, 
usually 20-25 base pair long, with a melting temperature around 60 ºC. They are used as a 
starting point for DNA synthesis. We designed them in a way that they amplified solely 
cDNA, and not the genomic DNA, with an amplicon size of 150-200 base pairs. This was 
achieved by searching for two consecutive exons, separated by an intron longer than 500 
base pairs. In cases where the introns did not have the minimum required size, one of the 
primers was designed to overlap an exon-exon junction, to obtain the same specificity. 
NCBI Primer-BLAST tool (https://www.ncbi.nlm.nih.gov/tools/primer-blast) allowed us to 
achieve all these requirements, and additionally, it provided an extra layer of specificity, 
making certain that the resulting amplicon was not amplifying unspecific regions by 
comparing its sequence within the Refseq mRNA database of NCBI. Used primers are 
shown below (Table XIV). 
Table XIV: Primers 
 Primer Name Sequence 
βACTIN FWD CTAGGCACCAGGGTGTGAT 
βACTIN REV CCATGTTCAATGGGGTACTT 
TNFα FWD CAAAGGGATGAGAAGTTCCC 
TNFα REV TGGTGGTTTGCTACGACGT 
GLUT4 FWD GACGACGGACACTCCATCTG 
GLUT4 REV TGCCACAATGAACCAGGGAA 
3.2.8.3. Quantitative PCR (qPCR) Technique used for detection and quantification of 
gene expression. It is based on a standard PCR technique, described in the previous 
section, with one difference being the inclusion of quantitative control of the amplification 
of the DNA. This is achieved with the use of cyanine dye called SYBR-GREEN, which is 
used as a double-stranded nucleic acid stain. As the DNA is being amplified, the dye itself 
forms complexes with the DNA, and we, in turn, measure the emitted light. 
Before we could run the qPCR, we had to prepare our samples, which we obtained with 
reverse transcription, by diluting them 1:20 with mQ H2O, to a final volume of 50 µL. 
Depending on the number of samples and which gene expressions we were interested in, 
we prepared either full, 96-well 200 µL plates, or an adequate number of 8 wells strips 
with the same volume. Into these wells, we dispensed the mix containing 1,875 µL of both 
forward and reverse primer of the desired gene, both at 10 µM, and 6,25 µL of Master Mix 
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2X containing SYBR-GREEN dye. Next, into these wells, we added 2,5 µL of cDNA of 
the samples we were interested in, and we loaded that into 2 wells, as we ran the samples 
in duplicates, for more reliable results. These prepared plates or strips were centrifuged for 
1 minute at 1000 rpm and were ready to be put in the machine. Nevertheless, we could not 
yet start the process, as it was necessary to prepare a set-up for the qPCR machine, which, 
in turn, was done with the use of online tools provided by Thermo Fisher Cloud. Samples 
were put in the machine, the set-up was uploaded with the use of a USB flash drive, and 
the process began. After the amplification was finished, the samples were disposed, and the 
acquired data was uploaded to a USB flash drive and later to Thermo Fisher Cloud for 
further analysis.   
Table XV: Temperate programme for the PCR 
Step Time at the set temperature Temperature 
Pre-denaturation (1x) 10 minutes 95 °C 
Denaturation and 
elongation (40x) 
15 seconds 95 °C 
1 minute 60 °C 
Melting curve 
(continuous) 
15 seconds 95 °C 
1 minute 
60 °C (gradually achieved 
with 1,6 °C/second change) 
15 seconds 
95 °C (achieved gradually 
with 0,1 °C/ second change) 
 
For the data analysis, we needed to minimize the experimental inconsistencies that can 
present themselves during the running of this process. For this, we used mouse β-actin, as 
this is a constitutively expressed in tissues and enables the normalization of target genes’ 
levels under the effect of GW3965. For each gene analysed, its primer efficiency was 
calculated using the standard curve method. Briefly, from a cDNA pool, a serial dilution 
bank was prepared. Using a dilution factor of 2 we prepared eight dilutions from 1:10 to 
1:640 plus a negative control with water. RT-qPCR was run with the same process used as 
described above, to obtain the data for the standard curve. R2 was calculated to check the 
accuracy of the regression line obtained. The efficiency of the primers was calculated, and 
the obtained curve equations were later used for the relative quantification of the samples 
from the tissues. 
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Finally, for each run, a melting curve was also performed. This step, done at the end of the 
40 cycles of the RT-qPCR, was a simple way to check for a presence of multiple 
amplicons or possible primer-dimer artefacts in the samples, which would obscure results 
and make them not suitable for further analysis. The sample was heated to 95 °C, and then 
gradually the temperature was lowered at the rate of 1,6 °C per second to the temperature 
60 °C. While the samples were cooling down, we measured the changes in fluorescence 
intensity.  
 
3.2.9. Statistical Analysis 
All the data we gathered during the above-mentioned experiments were analysed with the 
use of computer software GraphPad Prism 8. For the statistical comparisons between the 
data sets, we used two-way analysis of variance or ANOVA test, with Tukey correction for 
multiple comparisons using statistical hypothesis testing.  
For the protein activation analysis, the obtained levels of phosphorylated AKT and JNK 
were quantified with the use of ImageJ program. The same software was used for the 
quantification of the total AKT and β-actin, which was used for the normalisation of the 
data for phosphorylated AKT and JNK, respectively. The calculations were done with the 
Microsoft Excel software, and the data were then transported to GraphPad Prism for 
statistical analysis and graph drawing.  
For the analysis of the RNA expression levels of GLUT4 and TNF-α, we first obtained the 
concentration of the cDNA in each individual sample from the previously obtained 
standard curve equation. This data was then analysed with the use of relative quantification 
algorithm, where β-actin was used to normalise the obtained data and with this, we 
received relative RNA expression of both genes we were interested in. These calculations 
were done in Excel, with Prism being used for the graph generation and statistical analysis. 
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4. Results 
For this study, we compared WT to Pp5-deficient mice. For each genotype, three groups of 
8 male mice were prepared. At the age of 4 weeks, two groups of each genotype were 
subjected to an HFD while the rest were left on an SD for 10 weeks. In the last 2 weeks, 
one group of each genotype on HFD was daily treated with the LXR agonist GW3965 (20 
mg/kg), dissolved in a vehicle of CMC, while another group was treated solely with the 
CMC vehicle. GTT and ITT were performed after 10 and 12 days, respectively, of 
treatment during the last week. Afterwards, the animals were sacrificed and tissues (liver, 
adipose tissue and skeletal muscle) were collected and frozen at -80 ºC until they were 
needed. 
 
4.1. Analysis of the Pp5 Gene Knockout 
In addition to PCR genotyping of all mice at the age of 4 weeks, mice genotype was also 
routinely assessed by immunoblot analysis of the collected tissues. Fig. 8 shows a 
representative experiment of this type of analysis. 
 
Figure 8: Immunoblot assessment of the genetic ablation of the Pp5 gene. Protein extracts from the 
epidydimal adipose tissue (10 µg/lane) were analysed by immunoblotting using an antibody against Pp5. 
Samples 502, 503, 504, 505, 506 and 507 were from WT and 520, 521, 649, 522, 524 and 641 were from 
Pp5-deficient mice. (WT – wild type).  
From Fig. 8 we can clearly see the signal of Pp5 in samples from WT mice, and lack of the 
signal in samples obtained from Pp5-knockout mice.  
 
4.2. Growth Curve 
At the age of 4 weeks, mice were subjected to SD or HFD for the following 10 weeks and 
weight was measured weekly. The growth curve is shown in Fig. 9. 
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Figure 9: Growth curve of WT and Pp5-knock-out mice on SD and HFD. The graph represents body 
weight (in grams) of mice along the 10 weeks on SD or HFD, as indicated. Data represents mean ± standard 
deviation; * denotes significant difference between the WT groups (* 0,05˃p˃0,01; ** 0,01˃p˃0,001; *** 
0,001˃p˃0,0001; **** 0,0001˃p); # denotes significant difference between Pp5-knockout groups (# 
0,05˃p˃0,01; ## 0,01˃p˃0,001; ### 0,001˃p˃0,0001), (n≥8 animals per group). (WT – wild type; SD – 
standard diet; HFD – high-fat diet). 
 
From the graph, we can clearly distinguish the 2 groups, the one in HFD in which mice 
gained more weight and become obese, and the one in SD that remain lean. After the 6/7 
weeks, there is a significant statistical difference between mice on SD versus HFD, 
regardless of the genotype. Additionally, there was no statistical difference between WT 
and Pp5-knockout mice on the same diet, either SD or HFD. 
 
4.3. Glucose Tolerance Test (GTT) 
After 10 days of treatment with the LXR agonist, a GTT was performed. Mice were 
starved for 6 h and, just before the start of the test, weighted and basal glycemia 
determined in the blood of the tail vein with a glucometer. Glucose (2 g/kg) was injected 
with the syringe into the peritoneal cavity and glycemia determined again after 30, 60 and 
90 min. The data was analysed, and graph charts shown in Fig. 10 were obtained. 
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Figure 10: Glucose Tolerance Test. A) Glycemia of mice from the different groups at the indicated time 
points. B) AUC of the graph in A. Data represents mean ± SEM; * above the column denotes statistical 
difference when compared to the SD of the WT mice or KO mice, with * above the line denotes the statistical 
difference when comparing columns connected with the line; (**** 0,0001˃p); # denotes statistical 
difference when comparing different genotypes on the same diet and treatment; (# 0,05˃p˃0,01). (AUC – 
area under the curve; SEM – standard error of the mean; SD – standard diet; HFD – high-fat diet; WT – wild 
type; KO – knock-out). 
From Fig. 10 we can clearly notice considerable differences in the glucose tolerance 
depending on the diet and treatment with GW3965 but not between WT and Pp5-deficient 
mice in the same experimental condition of diet and treatment. In both WT and Pp5-
knockout groups, mice that were fed with an HFD performed worse in the GTT, indicating 
that these animals have lost their ability to lower these levels and are glucose intolerant. 
This can also be said when we compared animals that were treated with the GW3965, as 
blood glucose levels were also increased when compared to the SD groups. However, 
GW3965 treated mice also had significantly lower levels of glycemia when compared to 
vehicle-treated animals, indicating that the LXR ligand alleviates glucose intolerance 
induced by HFD/obesity. 
When we compared the different genotypes between each other, the only difference that 
we could notice was a slightly better performance in the GTT of the Pp5-knockout animals 
compared to WT ones but only in the SD condition. 
 
4.4. Insulin Tolerance Test (ITT) 
In addition to GTT, a similar test called ITT was performed on day 12 of treatment with 
the LXR ligand. Similarly, mice were starved for 6 h, and weight and basal glycemia was 
measured before starting the test. Afterwards, insulin (0,5 UI/kg) was intraperitoneally 
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injected to the mice and glycemia was measured after 30, 60 and 90 min. The gathered data 
was analysed, and the following graphs were obtained.  
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Figure 11: Insulin Tolerance Test. A) Glycemia of mice from different groups at the indicated time points. 
b) AUC of the graph in A. Data represents mean ± SEM; * above the column denotes statistical difference 
when compared to the SD of WT or KO mice, with * above the line denotes the statistical difference when 
comparing columns connected with the line; (** 0,01˃p˃0,001; **** 0,0001˃p); # denotes statistical 
difference when comparing different genotypes on the same diet and treatment; (# 0,05˃p˃0,01). (AUC – 
area under the curve; SEM – standard error of the mean; SD – standard diet; HFD – high-fat diet; WT – wild 
type; KO – knock-out). 
In Fig. 11 there is a clear and significant difference seen when we compare glucose levels 
between mice kept on SD and HFD, in both genotype groups. Animals on HFD displayed 
higher levels of glucose in their bloodstream, signifying that their tissues became less 
sensitive to insulin and thus tissue intake of glucose is defective. But, when we compared 
the animals treated with GW3965 to the untreated obese ones, they displayed lower 
glycemia and thus an increased response to insulin, although not at the same levels as mice 
on SD.  
When the comparison between genotypes was made, the only significant difference 
occurred in mice that were on the SD, with animals on HFD, treated and untreated alike, 
showing no discrepancy. 
 
4.5. Insulin Receptor Signalling Analysis 
We analysed insulin response in 3 different tissues where insulin effects are most 
prevalent: skeletal muscle, epidydimal white adipose tissue and liver. Activation by 
phosphorylation of AKT was analysed as bona fide reporter of insulin receptor signalling 
activation. Analyses were performed by immunoblotting using specific anti-phospho-AKT 
antibodies and normalized by pan-specific-AKT.  
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4.5.1. Skeletal Muscle Tissue 
4.5.1.1. Analysis of Insulin-Induced Activation/Phosphorylation of AKT  
We decided to analyse the phosphorylation levels of AKT as this enzyme regulates a key 
step in the insulin receptor signalling pathway. For normalisation, we determined the 
overall amount of AKT independently of its phosphorylation state. With the obtained 
results and calculated ratios, the following figure (Fig. 12) was obtained. 
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In the mice that were fed with SD, we can see an increase in AKT phosphorylation in mice 
that were injected insulin, both in WT and Pp5-knockout groups. This increase is 
statistically significant showing that AKT, and hence insulin receptor signalling, is 
activated, regardless of the mice genotype (Fig. 12A). 
On the contrary, in mice on HFD plus treatment with vehicle insulin did not induce AKT 
phosphorylation (Fig. 12B) regardless of the genotype. These results indicated that insulin 
Figure 12: Analysis of activated AKT (pAKT) 
in skeletal muscle tissue. A) Mice on SD B) 
Mice on HFD that were treated with just the 
vehicle. C) Mice on HFD that were treated with 
GW3965. Data represents mean ± SEM; * above 
the column denotes statistical difference when 
compared to the results in the same genotype with 
and without insulin; (** 0,01˃p˃0,001); # denotes 
statistical difference when comparing different 
genotypes with the same insulin option; (## 
0,01˃p˃0,001). (SD – standard diet; HFD – high 
fat diet; SEM – statistical error of the mean). 
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has no significant effects, because of the obesity associated with the HFD induced insulin 
resistance. 
Finally, mice on HFD that received GW3965 did not seem to show improvement in 
phosphorylation of AKT in response to insulin (Fig. 12C), and this effect was displayed 
similarly in WT and Pp5-deficient mice. 
4.5.1.2. Analysis of Activation/Phosphorylation of JNK 
JNK is an important protein kinase that is activated by pro-inflammatory signals and by 
stress stimuli and thus plays an important role in the immunological response and in the 
development of insulin resistance. In fact, the activation/phosphorylation of JNK is a 
marker of insulin resistance. Therefore, we analysed the JNK phosphorylation level using 
immunoblot analysis with anti-phospho-JNK antibodies. In this case, normalization to the 
expression level of reference protein β-actin was performed.  
In skeletal muscle tissue, we did not detect JNK phosphorylation in any of the conditions 
(data not shown).  
 
4.5.2. Epidydimal White Adipose Tissue 
4.5.2.1. Analysis of Insulin-Induced Activation/Phosphorylation of AKT  
As it was the case in skeletal muscle samples, in epidydimal white adipose tissue the 
phosphorylation of AKT was analysed by immunoblotting (Fig. 13).  
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As expected, there is a statistically significant difference between mice fed on SD, that is, 
phosphorylation of AKT is much higher in mice that were injected with insulin 15 minutes 
before being sacrificed, and this is true in both WT and Pp5-knockout mice groups (Fig. 
13A). 
When we analysed the data gathered from mice that were fed HFD (Fig. 13B), we 
observed no statistical difference between groups, not within same genotype groups 
(response to insulin), nor when comparing different genotypes. This indicates that these 
mice developed insulin resistance because of the HFD influence. 
Ultimately, when we looked at the data obtained from mice fed with HDF and treated with 
GW3965, although there seems to be some response to insulin in both genotypes, statistical 
significance was not achieved and only a tendency of response to insulin in terms of AKT 
phosphorylation was observed. This held true for comparison between mice in the same 
genotype as well as we compared WT to Pp5-knockout mice. 
4.5.2.2. Analysis of Activation/Phosphorylation of JNK 
JNK phosphorylation was analysed in this tissue and is shown in Fig. 14. According to the 
literature, JNK phosphorylation increases in obesity, and according to our results GW3965 
treatment counteracts this increase. Both effects are produced regardless of the genotype.  
Figure 13: Analysis of activated AKT 
(pAKT) in epididymal white adipose 
tissue. A) Mice on SD B) Mice on HFD that 
were treated with just the vehicle 5 C) Mice 
on HFD and treated with GW3965. Data 
represents mean ± SEM; * above the column 
denotes statistical difference when compared 
to the results in the same genotype with and 
without insulin; (* 0,05˃p˃0,01; ** 
0,01˃p˃0,001). (SD – standard diet; HFD – 
high fat diet; SEM – statistical error of the 
mean). 
 
44 
 
WILD TYPE KNOCK OUT
0.0
0.2
0.4
0.6
0.8
1.0
p
J
N
K
/A
C
T
IN
 r
e
la
ti
v
e
 l
e
v
e
ls
SD
HFD+CMC
HFD+GW
*
****
***
 
Figure 14: Analysis of activated JNK (pJNK) in epididymal white adipose tissue in mice of the indicated 
groups and genotypes. Data represents mean ± SEM; * above the column denotes statistical difference when 
compared to the results of SD mice in the same genotype; * above the line denotes the statistical difference 
when comparing columns connected with the line; (* 0,05˃p˃0,01; *** 0,001˃p˃0,0001; **** 0,0001˃p). 
(SD – standard diet; HFD – high-fat diet; SEM – statistical error of the mean; CMC - carboxymethyl 
cellulose). 
In white adipose tissue, we saw the increased levels of activation of JNK in WT and KO 
animals which were fed HFD. In WT mice, although GW3965 seemed to lower the JNK 
activation, statistically this was not significant. However, when we analysed KO animals, 
there was a clear and significant lowering of JNK phosphorylation, almost to the same 
level as in animals on SD. 
 
4.5.3. Liver 
4.5.3.1. Analysis of Insulin-Induced Activation/Phosphorylation of AKT 
The procedure of obtaining phospho-AKT results from the liver tissue matched the ones 
used for muscle and epidydimal white adipose tissue. Total AKT was used for 
normalisation purposes. Results are shown in Fig. 15. 
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In the liver, we noticed a huge discrepancy when compared to the results obtained from 
muscle and epididymal white adipose tissue, as activation of AKT was significantly 
different for conditions in this tissue. Mice fed with SD showed no significant tendency for 
AKT phosphorylation increase in response to insulin, in neither of the genotypes. Other 
data from this tissue was hard to interpret, as the data spread was wide, and no clear 
conclusion could be drawn.  
4.5.3.2. Analysis of Activation/Phosphorylation of JNK 
Just as we did in epididymal white adipose tissue, we tested the phosphorylation levels of 
JNK in liver samples. The process was identical to the one used in that case, with the same 
antibody used and actin used as a reference protein for normalisation. Processed data gave 
the results shown in Fig. 16. 
Figure 15: Analysis of activated AKT 
(pAKT) in liver tissue. A) Mice on SD B) 
Mice on HFD that were treated with just the 
vehicle. C) Mice on HFD and treated with 
GW3965. Data represents mean ± SEM; * 
above the column denotes statistical 
difference when compared to the results in 
the same genotype with and without insulin; 
(* 0,05˃p˃0,01; ** 0,01˃p˃0,001). (SD – 
standard diet; HFD – high fat diet; SEM – 
statistical error of the mean). 
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Figure 16: Analysis of activated JNK (pJNK) in liver tissue in mice of the indicated groups and 
genotypes. Data represents mean ± SEM; * above the column denotes statistical difference when compared to 
the results of SD mice in the same genotype, with * above the line denotes the statistical difference when 
comparing columns connected with the line;  (** 0,01˃p˃0,001; *** 0,001>p>0,0001); # denotes significant 
difference when comparing between genotypes; (## 0,01˃p˃0,001). (SD – standard diet; HFD – high-fat diet; 
SEM – statistical error of the mean; CMC - carboxymethyl cellulose). 
When we evaluated these results, we saw that JNK is not significantly more 
phosphorylated in the animals which were kept on HFD, regardless whether their Pp5 gene 
was deleted. With closer inspection of WT mice, we saw that GW3965 did not display any 
significant effects on JNK activation, as levels in these mice were insignificantly different 
from non-treated mice or mice on SD.  The data in KO animals is a different story 
altogether, with JNK activation increased in both groups on HFD, although only the 
comparison between the SD group and the HFD group treated with GW3965 is statistically 
significant. Also significant is the difference between KO HFD groups, with an increase 
noted in the treated animals. 
Once we compared the genotypes, we could only see the increase of JNK activation in KO 
treated animals 
 
4.6. RNA Analysis 
Next, we analysed relative levels of gene expression of TNF-α, a pro-inflammatory 
signalling cytokine, and GLUT4, glucose transporter responsible for glucose intake in 
response to insulin in many tissues. Just as in the case of protein evaluation, a reference 
element was required for normalisation purposes, with this time gene for βactin being used 
in both for TNF-α and GLUT4 analysis. βactin gene is constitutively present and as such 
serves its purpose of a reference gene.   
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All the experiments we carried out in similar ways. After the whole procedure was 
conducted, the data that we obtained was transferred onto a computer and there analysed. 
The melting curve was performed for all the reactions, and the analysis showed the 
amplification process was successful and primer-dimers were not present in any of the 
reactions (data not shown). 
 
4.6.1. Skeletal Muscle 
4.6.1.1. Relative Expression of GLUT4 
With the data obtained in the quantitative PCR experiment, Figure 17 shows the results for 
GLUT4 gene expression in skeletal muscle. 
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Figure 17: Analysis of relative GLUT4 gene expression in skeletal muscle tissue of both mice genotypes, 
subjected to the indicated diets and treatments. Data represents mean ± SEM; * above the column denotes 
statistical difference when compared to the results of SD mice in the same genotype (** 0,01˃p˃0,001; **** 
0,0001˃p). (SD – standard diet; HFD – high-fat diet; SEM – statistical error of the mean; CMC - 
carboxymethyl cellulose). 
From these results, we can observe a clear and significant decrease in the expression of the 
GLUT4 in the animals on HFD, in both WT and Pp5-knockout subjects. As reported in the 
literature (38), obesity-associated insulin resistance correlates with a decreased expression 
of GLUT4 gene expression. We recapitulated this observation in WT mice and assessed 
that Pp5-deficient mice behaved similarly. There is also a small increase of GLUT4 
expression in WT animals that received the GW3965 treatment, although statistically, from 
our results, this is not significant when compared to animals that did not receive the LXR 
ligand. 
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4.6.1.2. Relative Expression of TNF-α 
With the data obtained from the quantitative PCR experiment, Fig. 18 shows the results for 
TNF-α gene expression in skeletal muscle. 
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Figure 18: Analysis of relative TNF-α gene expression in skeletal muscle tissue of both mice genotypes, 
subjected to the indicated diets and treatments. Data represents mean ± SEM; * above the column denotes 
statistical difference when compared to the results of SD mice in the same genotype (* 0,05˃p˃0,01; (** 
0,01˃p˃0,001). (SD – standard diet; HFD – high-fat diet; SEM – statistical error of the mean; CMC - 
carboxymethyl cellulose). 
Obesity induces a low-grade chronic inflammatory response in the adipose tissue that, 
eventually, could turn out systemically, and the increased expression of the TNF-α gene is 
a good marker of this process (39). We can clearly see the increase of the TNF-α gene 
expression in the WT mice that were part of HFD groups, both in and knockout genotypes. 
These results affirm that in obese individuals, stress situation is exasperated, and 
inflammatory response occurs. 
When we compared the treated animals with untreated ones, no significant difference was 
observed. This indicates that the GW3965 does not affect the inflammatory pathway, and 
this is not the mechanism of potential antidiabetic action of this compound. 
Additionally, when the comparison between the genotypes was made, no difference was 
noticeable and thus indicating that the Pp5 does not affect this pathway. 
 
4.6.2. Epididymal White Adipose Tissue 
4.6.2.1. Relative Expression of GLUT4 
With the data obtained in the quantitative PCR experiment, the following figure for the 
GLUT4 from epididymal white adipose tissue was obtained (Fig.Figure 19). 
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Figure 19:Analysis of relative GLUT4 expression in epididymal white adipose tissue of both mice 
genotypes, subjected to the indicated diets and treatments.  Data represents mean ± SEM; * above the column 
denotes statistical difference when compared to the results of SD mice in the same genotype (* 0,05˃p˃0,01; 
** 0,01˃p˃0,001; **** 0,0001˃p); # denotes significant difference when comparing between genotypes; (# 
0,05˃p˃0,01). (SD – standard diet; HFD – high-fat diet; SEM – statistical error of the mean; CMC - 
carboxymethyl cellulose). 
As it was the case in the muscle tissue, the epididymal white adipose tissue also showed a 
decrease in the expression levels of GLUT4 in mice that were fed the HFD, in both 
untreated animals and in treated ones, again signalling lower insulin sensitivity and lower 
glucose intake, in both WT and knockout genotypes, further affirming previous results. An 
interesting result can be observed in the KO genotype, where we can see that the mice that 
were treated with the GW3965 showed higher levels of GLUT4 expression, and in fact, 
these levels and the levels of GLUT4 expression of KO mice on SD are not significantly 
different. This result is compelling for further research into the Pp5 gene and GW3965 like 
compounds, as it seems they have a tangible positive effect in the antidiabetic treatment. 
4.6.2.2. Relative Expression of TNF-α 
With the data obtained in the quantitative PCR experiment, the following figure for the 
TNF-α from epididymal white adipose tissue was obtained (Fig.Figure 20). 
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Figure 20: Analysis of relative TNF-α expression in epididymal white adipose tissue of both mice 
genotypes, subjected to the indicated diets and treatments.  Data represents mean ± SEM; * above the column 
denotes statistical difference when compared to the results of SD mice in the same genotype, with * above 
the line denotes the statistical difference when comparing columns connected with the line (* 0,05˃p˃0,01); 
# denotes significant difference when comparing between genotypes; (# 0,05˃p˃0,01). (SD – standard diet; 
HFD – high-fat diet; SEM – statistical error of the mean; CMC - carboxymethyl cellulose). 
Results in the WT group show a clear increase of the TNF-α expression in these animals, 
which correlates with the results obtained from the muscle tissue. Yet, mice that were 
treated with the GW3965 show increase in the TNF-α when compared to the untreated 
mice, an interesting result that needs to be further looked into.  
However, the results from the knockout group are somewhat perplexing, as no significant 
differences were observed between any of the three groups. Further tests would be needed 
to shine the light on these results. 
Finally, we observed a difference when we compared treated WT and knockout animals; 
we saw a decrease in TNF-α expression in the latter group. Although the really high levels 
of TNF-α in the treated WT animals make drawing conclusions somewhat more difficult, it 
still shows that these animals, when taking into consideration the Pp5 KO and the 
treatment with the GW3965, have lower levels of inflammatory signalling molecules and 
thus can provide clues that these 2 factors have tangible effects on the inflammation-
induced insulin resistance. 
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5. Discussion 
Obesity is one of the main factors in the development of insulin resistance and 
consequently, type 2 diabetes, and a number of patients with this disease are growing, it 
represents a field with an ever-growing need for new medications. 
First, we had to establish the basis of our work, which were genetically modified mice, and 
test if the gene deletion was successful (Figure 8), and once that was tested, we could move 
with further experiment. One of the first analyses we conducted was the growth curve, to 
see if the gene modification has any effect on the development of the animals and if it 
indeed has, what kind. What we have discovered is that Pp5 gene deletion has no impact 
on the growth of animals, as we can clearly see that the animals kept on HFD gained 
weight irrespectively of their genotype, and same goes for the mice on SD (Figure 9). This 
indicated that Pp5 does not play a role in the development of diet-induced obesity.  
When we look at the results of the glucose tolerance tests, where we injected mice with 
glucose and then measured glycemia at different time points, we could observe an 
interesting set of results. Mice that were fed HFD had considerably worse glucose 
tolerance, as data shows that their systemic glucose levels are much higher when compared 
to animals on SD. This is as expected, as the HFD ingestion causes the development of 
insulin resistant tissues, and thus glucose is not transported into the tissues. Additionally, 
tissues of animals that were treated with the GW3965, although not as responsive to 
glucose as their SD counterparts, were still more responsive to insulin signalling. In 
addition, levels of blood glucose in these animals are lower when compared with the 
untreated animals. This indicates that the LXR ligand systemically improves the glucose 
tolerance, a result that could be of big importance, as it means that medications from this 
group of molecules could represent a new way of diabetes treatment. And when we 
consider what role Pp5 plays in glucose tolerance, the data seems to suggest that it has no 
important impact in this process, as both WT and KO group glucose levels are matching 
(Figure 10). These results are corroborated further with the insulin tolerance tests. Here we 
injected mice with insulin and again measured their glucose levels in different time frames. 
Animals on SD displayed lower glucose levels, thus indicating that their tissues are 
responding to the injected insulin. And animals on HFD had higher levels of glucose, 
signalling that their tissues are more insulin resistant. Once again, GW3965-treated 
animals displayed better insulin signalling when compared to untreated animals, but not on 
the same level as the animals on SD. Nonetheless, Pp5 does not seem to influence the 
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insulin signalling, as results of systemic glucose levels of both genotypes matched each 
other’s (Figure 11). From these results, we can conclude that GW3965, in fact, has a 
positive effect on insulin signalling, regardless of the genotype. 
For the insulin receptor signalling analysis, we chose 3 tissues: muscle, liver and white 
adipose tissue. Although insulin affects almost all type of tissues, the three chosen tissues 
represent primary sites of insulin actions, such as glucose intake, glycogenesis and fatty 
acid synthesis, among others. Right before sacrificing the mice, some were injected with 
insulin, to see what kind of an effect the diet has on the insulin signalling pathway. First, 
we analysed the phosphorylation of AKT in muscle tissue, a protein that is activated 
through phosphorylation when insulin binds to insulin receptors. In animals on SD, we 
could clearly see that when subjects have insulin injected, AKT is significantly 
phosphorylated, indicating that insulin signalling pathway is functioning properly and 
showing that mice kept on SD did not develop insulin-resistant tissues; again this feature 
was independent of the genotype analysed (Figure 12A). In subjects fed with HFD, the 
data show that statistically there was no change in AKT phosphorylation between the 
animals injected with insulin when compared to mice which were not injected with insulin 
(Figure 12B) and this held true for both WT and Pp5-knock out mice. These results 
indicate that these animals did develop insulin resistance, as this was the effect of their 
diet, and in this process, Pp5 played no significant part as intercomparisons resulted in no 
observed differences. We also observed that Pp5 does not play any essential role in how 
GW3965 affects mice, regardless of the presence of insulin (Figure 12C). Comparable 
results were obtained in the epididymal white adipose tissue, as again we saw that animals 
on SD retained their insulin sensitivity. Here, AKT was significantly more activated in 
both WT and KO mice which were injected with insulin before being sacrificed when 
compared to animals without insulin injection (Figure 13A), with genotype showcasing no 
influence. Furthermore, again we could see that mice that were on HFD did develop insulin 
resistance, regardless of their genotype, as both WT and KO showed the same level of 
phosphorylation of AKT regardless of the presence of the insulin or their genotype (Figure 
13B). And once again, just as it was observed in the muscle tissue, we can see that Pp5 
deletion did not interfere in how GW3965 affected this tissue (Figure 13C). When we 
checked phosphorylation of AKT in liver though, results were not so conclusive. 
According to obtained data, statistical analysis did not show any differences in any of the 
comparisons, in any of the graphs, not even between the mice on SD (Figure 15). This was 
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somewhat unexpected, as previous results showed clearly that these animals have retained 
insulin signalling and their AKT phosphorylation is evident, but this was not the case in the 
liver samples. Likewise, mice kept on HFD and the mice that were on this diet and were 
treated with the GW3965 did not provide any firm evidence about the influence of these 2 
conditions on the AKT activation in liver tissue. Further analyses are needed to discover 
whether liver tissue does, in fact, react differently to this LXR agonist under the influence 
of insulin when compared to muscle and white adipose tissues, and if it does, what is the 
reason behind this unique reaction to these stimuli. Alternatively, the liver might need a 
longer exposure to insulin to activate AKT than the adipose tissue or skeletal muscle.  
We were also interested in the expression levels of JNK in the same tissues. By analysing 
the activation of JNK in these tissues, we can get a better characterization of inflammation 
processes and subsequent insulin insensitivity. For JNK activation we were more interested 
in how it is represented in a condition where insulin was not injected into the animals, so 
we are only showing results for those animals. When we inspected samples obtained from 
muscle tissues, we saw that we could not properly quantify results, as experimentally we 
did not detect JNK phosphorylation in any of the animals. We did, however, obtain results 
for the other two tissues. In epididymal white adipose tissue, we saw an increase in JNK 
phosphorylation in mice which were on HFD, when compared to the subjects on SD, in 
both WT and KO groups. What was quite interesting, however, was what happened in the 
HFD group which was injected with GW3965. In KO group we observed noticeable 
lowering of JNK activation when compared to the animals which were not injected with 
the LXR ligand, to the levels that were statistically no different to KO mice on SD. And 
although WT mice did not display the same decrease in JNK activation, it still appears that 
GW3965 had a similar effect, although not statistically important (Figure 14). This is a 
result that seems to indicate that GW3965 affects the inflammation in the white adipose 
tissue, and in fact lowers it, which could provide to be beneficiary in the therapy of 
diabetes. Lowering the inflammation would result in a decrease of insulin resistance, as 
these 2 processes are interlinked, and so with lower inflammation, one might expect better 
insulin signalling. Further experiments in the liver were not so conclusive though. In the 
WT animals, if we compare treated animals with non-treated ones, although statistical 
analysis did not indicate significant differences, there seems to be an indication that 
GW3965 does affect JNK activation and lowers it. Pp5-knock out mice, however, showed 
somewhat contradictive results, as treated subjects showed a significant increase in JNK 
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activation in both comparisons to SD and HFD untreated mice (Figure 16). Just as it is in 
the AKT analysis, liver again displayed interesting results, and definitely deserves greater 
attention and more thorough research done, to see if these results could be reproduced and 
if they are, why does this tissue react so differently when compared to muscle and 
epididymal white adipose tissues. 
In the next step, we decided to analyse the expression of certain genes at the level of 
transcription. We decided to test for 2 genes: Slc2a4, which encodes GLUT4, and the 
TNF-α gene. Slc2a4 was chosen because the main pathway of insulin-induced glucose 
intake in the majority of tissues contains the GLUT4 transporter. And as TNF-α is a 
systemic cytokine and is deeply involved in systemic inflammation, along with observed 
anti-inflammatory action of GW3965, in epididymal white adipose tissue at least, this gene 
was of a great interest, as it could explain the mechanism of LXR ligand actions. The 
expression of these 2 genes was investigated with the use of quantitative-PCR experiments, 
and we analysed them in 2 of the previously used tissues: skeletal muscle and epididymal 
white adipose tissue. As protein analysis in liver gave some discrepancies when compared 
to results from other tissues, we decided to focus on adipose and muscle tissues and so did 
not analyse liver samples, although this tissue still remains very intriguing and deserves 
more detailed research. 
In skeletal muscle, GLUT4 levels were highest in the animals which were fed with SD, 
with subjects on HFD showed significantly lower levels, in both WT and KO groups. This 
indicates that insulin controls the expression of the GLUT4 transporter and when the 
signalling resistance occurs, these tissues do not intake glucose as they do in physiological 
conditions, resulting in hyperglycaemia. When we compared animals which were treated 
with the GW3965 to the ones that were not, statistically we did not observe any important 
discrepancies, although WT group of treated animals does seem to be responding to the 
treatment, as the Slc2a4 gene is trending to greater expression when compared to not 
treated animals. Meanwhile, KO mice do not display any noticeable differences, as 
expression levels in both groups on HFD are showing the same levels of gene expression 
(Figure 17). In the epididymal white adipose tissue, the obtained results were just as 
interesting. Again, just like in the case of muscle, we see that the GLUT4 is more 
expressed in SD groups, in both genotypes, when comparing to HFD fed subjects. This 
affirms the previous results and does indicate that Slc2a4 expression is greatly decreased in 
diet-induced obesity and the resulting inflammation. Next, if we take a look at the WT 
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mice, we can see that treated animals are displaying same levels of expression as the 
untreated ones, indicating that here, GW3965 does not display any tangible effect. But, in 
the KO group, we encounter an interesting result, as the mice which were treated with the 
LXR ligand displayed higher levels of Slc2a4 expression when compared to the untreated 
mice. Moreover, they showed the same levels of expression of this gene as the animals on 
SD. This is a result that could be of high importance, as it indicates that LXR ligands, such 
as GW3965, affect the expression and subsequently the translocation of GSV and the 
GLUT4 transporters in the epididymal white adipose tissue (Figure 19). We can connect 
this with protein analysis of JNK activation, and as JNK seems to be inhibited by 
GW3965, this improves insulin signalling, with one of the effects being higher gene 
expression and insulin-induced exocytosis of GLUT4 transporter. This could potentially 
mean that these molecules could work as antidiabetic drugs and could be used for treating 
the illness. This is a therapeutic strategy that has yet to be used extensively for this 
purpose. This result was obtained solely in the group that had Pp5 gene deleted, hinting at 
the possibility that this protein is also involved in this area as well, so for more clear 
answers, more studies will have to be conducted.  
Finally, we looked at the expression levels of TNF-α. In the skeletal muscle tissue, we can 
see that expression levels of this gene are noticeably lower in animals on SD, in both WT 
and KO subjects. This is as expected, as obesity induces inflammation processes, which 
TNF-α is a part of. Additionally, it seems that GW3965 does not have any effect on this 
cytokine expression, as treated and untreated mice had indistinguishable levels of TNF-α 
expression. This holds true in both WT and KO mice (Figure 18). From this result, we can 
say that GW3965 does not affect the inflammation process through inhibiting TNF-α 
expression. To determine how it does affect inflammation, as it was indicated in the protein 
analysis of epididymal adipose tissue, more research is needed. Likewise, we can say that 
Pp5 also does not affect this gene’s expression. Results from the epididymal white adipose 
tissue were a little more diverse. When we compared untreated animals on HFD with the 
ones on SD, we did not observe noticeable differences, regardless of the genotype. 
However, if we look at WT animals which were treated with GW3965, we saw a 
significant increase in the TNF-α expression, even when comparing to the same genotype 
that was not treated. Moreover, when we compared treated WT animals with treated KO 
animals, the KO group displayed significantly lower TNF-α expression (Figure 20). This 
result was complex and clearly needs to be explored in more detail, as it goes against 
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previously obtained data, signalling an increase in inflammation because of GW3965, and 
additionally occurring solely in WT animals. These 2 facts together are giving a solid 
request for more detailed research, as if they are corroborated with more evidence, this 
could mean that GW3965 and other ligands are not as promising as earlier data showed, 
and with the still unknown influence of Pp5 adding to the conundrum, present a fascinating 
future topic for research. 
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6. Conclusion 
The aim of our work was to investigate the influence of different mediators and genes in 
the occurrence of diet-induced obesity and in the development of insulin resistance. For 
this purpose, genetically modified mice were fed with different diets, to induce obesity in 
some of the animals. Tissues were gathered, and later protein and RNA analyses were 
conducted. In summation, from the data we obtained, we saw that the deletion of Pp5 gene 
did not influence the weight gain of subjects nor the response to LXR agonist GW3965. In 
both genotypes, we did observe that GW3965 does positively affect systemic glucose 
levels and insulin signalling when we compared these animals to the non-treated ones. 
These results lead us to conclude that GW3965 has the potential to be used as a medication 
for diabetes. Further tests were done with different proteins extracted from three different 
tissues. In all three investigated tissues, we saw that AKT activation was increased when 
animals on SD were injected with insulin, but the same did not occur in animals which 
were kept on HFD. As AKT plays an important role in the insulin signalling cascade, this 
decrease in its activation indicated that these tissues became insulin resistant because of 
obesity’s effects on them. We also saw that Pp5 does not play any significant role in this 
pathway of insulin signalling, as obtained data did not differentiate between the WT and 
KO mice. From the epididymal white adipose tissue and liver tissue, we saw that JNK 
activity is increased in subjects which were kept on HFD, as JNK is activated in 
inflammatory conditions, which do occur in diet-induced obesity. An interesting result in 
this experiment was that KO mice which were treated with LXR agonist displayed 
significantly lower levels of JNK phosphorylation, suggesting that these molecules could 
act as a mediator of the JNK signalling pathway, and in fact lower its activation and thus 
improving the insulin signalling. With this occurring solely in KO animals, where Pp5 was 
not present, it gives an interesting new area to research, to see if Pp5 also affects the 
inflammation signalling. This result though was not reproduced in the liver, and actually, 
some discrepancies occurred, with results from KO mice exhibiting higher levels of JNK 
activation compared to non-treated animals. These analyses were followed up by RNA 
investigation in muscle and epididymal white adipose tissue, where we checked the levels 
of expression of GLUT4 and TNF-α. We saw a significant decrease of GLUT4 expression 
in mice fed HFD when compared to the animals which were kept on SD, although an 
interesting result was obtained in the adipose tissue, where the test indicates that GW3965 
increased the expression of this transporter. This result could possibly explain how the 
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GW3965 improved systemic glucose levels which we observed earlier, as more GLUT4 
expression would result in more of this transporter being translocated to the cell membrane 
and more chance of glucose intake, at least in the adipose tissue. Again, data displayed that 
this only happens in KO subjects, alluring to another possible role of Pp5, this time in 
glucose transport. Finally, when we checked the expression levels of TNF-α, which were 
increased in both tissues in mice that were fed with HFD, regardless if they were treated 
with the LXR ligand or not. White epididymal tissue exhibited some anomalies when 
compared to the muscle tissue, as WT mice which were treated with GW3965 had 
significantly higher TNF-α levels.  
In conclusion, from our obtained data we can say that LXR ligands like GW3965 do 
improve insulin signalling and could be developed into a new medication group for 
obesity-associated diabetes. This is based on the data that GW3965 inhibited JNK 
signalling pathway, and with it, improved inflammation and insulin signalling, which then 
results in the higher levels of expression of Slc2a4 gene and consequently more exocytosis 
of GLUT4 to the cell membrane, as it was the case in the epididymal white adipose tissue. 
Thus, some positive data regarding LXR ligands were obtained, but more experimental 
evidence needs to be gathered before the true potential of these molecules can be 
established.  
The role of Pp5 in this area still remains to be uncovered though, as we could not draw any 
concrete conclusions about what role this protein plays in the insulin signalling pathway in 
different tissues. From the data we gathered we could state that Pp5 deletion, with 
concurrent use of GW3965, inhibits the activation of JNK, thus improving insulin 
signalling pathway, with the consequence being the higher expression of Slc2a4 gene. But 
some contradictory data also seem to be present, as liver samples especially displayed 
unusual behaviour, with Pp5 deletion causing an increase of JNK activation in the presence 
of GW3965. From all this evidence, one thing is clear, and that is the need for further 
research done in this field, as Pp5 still remains mostly a mystery and its effect in this whole 
story remains hidden, so more research must be carried out before any concrete influence 
of Pp5 on diet-induced obesity and insulin resistance can be given. 
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